Antiviral Activity of Turmeric (Curcuma longa) Against Potato Virus Y: In Silico Molecular Docking Analysis 

Antiviral Activity of Turmeric (Curcuma longa) Against Potato Virus Y: In Silico Molecular Docking Analysis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Antiviral Activity of Turmeric (Curcuma longa) Against Potato Virus Y: In Silico Molecular Docking Analysis Allam Arafat Megahed, Alaa Barakat, Ahmed Attya Embaby, Sonya Hamouda Mohamed, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7083267/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 03 Sep, 2025 Read the published version in Beni-Suef University Journal of Basic and Applied Sciences → Version 1 posted 18 You are reading this latest preprint version Abstract Background: This study explores the antiviral potential of turmeric-derived compounds, particularly curcuminoids, against Potato Virus Y (PVY) strain PVY N -Egypt through in silico molecular docking simulations. The binding interactions of curcumin, bisdemethoxycurcumin, demethoxycurcumin, isorhamnetin, and ribavirin with three key viral proteins—P1 protease, helper component proteinase (HCPro), and coat protein (CP)—were evaluated to assess their therapeutic potential. Results Molecular docking results showed that isorhamnetin had the strongest binding affinity for P1 protease, while curcumin and bisdemethoxycurcumin exhibited favorable binding to both HCPro and CP. The study further analyzed the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiles of the compounds, revealing that most ligands, except curcuminol and ribavirin, demonstrated good oral bioavailability and favorable gastrointestinal absorption. Toxicity concerns were noted for curcuminol and ribavirin. Curcumin and its derivatives, particularly isorhamnetin, emerged as promising antiviral candidates, with bisdemethoxycurcumin showing potential to inhibit viral replication. Ribavirin, while exhibiting moderate binding, presented fewer favorable interactions compared to curcumin derivatives. Conclusion This work provides valuable insights into the design of antiviral agents targeting PVY and suggests that curcumin derivatives may offer an effective solution for PVY management, warranting further experimental validation and optimization for agricultural and pharmaceutical applications. Antiviral activity Curcumin In silico Molecular docking Turmeric Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 1 Background Potato Virus Y (PVY) is one of the most prevalent and economically damaging viruses affecting potato crops worldwide effectively conveys the importance of the study. It belongs to the Potyvirus genus and is primarily transmitted by aphids. PVY infection can lead to a variety of symptoms, including mosaics, leaf curling, and stunting, ultimately resulting in reduced yield and quality of potatoes [ 1 , 2 ]. The virus is a major contributor to significant yield losses, particularly in temperate regions where it is considered endemic. Infected potato plants commonly display a range of symptoms, including mosaic leaf patterns, leaf curling, and discoloration of tubers. These symptoms not only reduce overall crop yield but also compromise the quality and marketability of the harvested produce. In severely affected fields, yield losses can reach up to 30%, resulting in considerable economic impact. Financial burdens are further amplified by the increased reliance on pesticides, elevated disease management expenses, and the loss of tubers that meet commercial standards [ 2 , 3 ]. In Europe and North America, losses associated with Potato virus Y (PVY) amount to millions of dollars each year, representing a major constraint on potato production and profitability [ 4 ]. In Egypt-one of the leading potato producers in the Middle East and North Africa (MENA) region-PVY poses a serious threat to sustainable cultivation. Potatoes rank among the country's most valuable agricultural export commodities, and reports of PVY infections have been on the rise, especially in the Nile Delta region, where much of Egypt’s potato farming is concentrated [ 5 , 6 ]. The virus not only affects yield but also diminishes the market value of the tubers, as symptoms reduce their quality and appearance, making them unsuitable for export. The economic burden in Egypt is further compounded by the lack of efficient control measures and the limited availability of resistant potato varieties. Given these challenges, the adoption of alternative control strategies-particularly plant-derived antiviral agents-has become increasingly vital to protect Egypt’s potato industry. At present, the management of PVY largely relies on chemical treatments, which raises significant concerns regarding environmental impact and the potential development of resistant viral strains [ 7 ]. As a result, there is growing interest in exploring more sustainable and effective solutions, including the application of natural, plant-based compounds for combating viral infections in crops [ 8 ]. Among these, curcumin—the principal bioactive compound in Curcuma longa (turmeric)—has attracted considerable attention due to its broad spectrum of biological activities, including antiviral, antibacterial, and anticancer properties [ 9 ]. Curcumin, the bioactive component of Curcuma longa (turmeric), has attracted significant attention due to its broad antiviral efficacy against several viruses, including HIV, Hepatitis B, and Influenza. This efficacy is primarily attributed to its ability to interfere with viral entry, replication, and modulation of the host immune response [ 10 , 11 ]. Molecular docking is a computational method frequently employed in drug development and structural biology to predict interactions between two molecules, typically a target protein and a small bioactive ligand [ 10 ]. This approach entails positioning the ligand within the active or binding site of a target protein and assessing the interaction's strength and specificity using scoring functions. These functions take into account key factors such as binding affinity, hydrogen bonding, hydrophobic interactions, and steric compatibility [ 12 ]. Molecular docking offers valuable insights into the molecular mechanisms underlying ligand–protein interactions, facilitating the identification of potential inhibitors or modulators for therapeutic or biotechnological use [ 13 ]. It is especially beneficial in in silico studies, enabling efficient virtual screening and optimization of candidate compounds prior to experimental validation [ 14 ]. Molecular docking has emerged as a powerful tool in the study of plant viruses, particularly in the development of antiviral agents aimed at controlling viral plant diseases. This computational technique enables researchers to investigate the interactions between key viral proteins—critical for processes such as replication, movement, and host infection—and potential inhibitory compounds derived from either synthetic sources or natural products [ 15 ]. By targeting essential viral elements, including RNA-dependent RNA polymerases, coat proteins, and helicases, molecular docking facilitates the identification of molecules capable of interfering with the viral life cycle [ 15 ]. This approach has proven especially useful in evaluating bioactive compounds from medicinal plants, many of which exhibit notable antiviral properties. For example, docking studies have been used to examine the binding of phytochemicals to the coat proteins of Tobacco mosaic virus (TMV) and Potato virus X (PVX), offering valuable insights into their potential to disrupt viral assembly or reduce infectivity [ 16 ]. Through high-throughput virtual screening and structural refinement, molecular docking significantly accelerates the discovery of environmentally friendly, plant-based antiviral agents to help reduce crop losses caused by plant viruses. Recent advancements in in silico molecular docking investigations have introduced new insights into the interactions between bioactive compounds and viral proteins [ 11 ]. These computational approaches allow investigators to deduce the binding affinity and molecular interactions between compounds and target viral proteins, offering valuable insights into their antiviral potential [ 17 ]. In the context of PVY, exploring curcumin's binding interactions with key viral proteins may provide a novel strategy for managing PVY infections in potatoes. As Egypt continues to face significant challenges from PVY, the development of integrated pest management strategies and the exploration of natural antiviral agents, such as curcumin, are becoming increasingly critical. This study aims to investigate the in silico molecular docking interactions between curcumin and key PVY proteins, evaluating its potential as a natural antiviral agent against this economically devastating virus. 2 Methods 2.1 Target proteins of PVY N -Egypt strain To ensure clarity and uniformity throughout the manuscript, all compound names (e.g., bisdemethoxycurcumin, demethoxycurcumin, isorhamnetin) have been consistently formatted in lowercase, following standard scientific nomenclature conventions. The target proteins selected in this study include P1 protease, helper component proteinase (HCPro), and coat protein (CP). Each protein plays a crucial role in the replication cycle of Potato Virus Y (PVY). P1 protease is involved in processing the viral polyprotein, HCPro acts as a suppressor of gene silencing and assists in viral movement, while the coat protein is essential for viral assembly and transmission. The amino acid sequences of three key proteins from Potato virus Y strain N-Egypt (Accession No. AAM81207) (Fig. 1 ) are provided. These proteins include: a) Potyvirus P1 Protease (pfam01577): This protease is involved in the processing of viral polyproteins. The sequence spans amino acids 1–200, with functional domains associated with viral replication and processing. b) Helper Component Proteinase (pfam00851): This protein is essential for virus transmission by aphids and functions a decisive work in the replication cycle. The sequence spans amino acids 1-421, with conserved regions associated with proteinase activity and aphid transmission. c) Potyvirus Coat Protein (pfam00767): The coat protein encapsulates the viral RNA, enabling viral stability and transmission. The sequence spans amino acids 1-241, containing key domains involved in the formation of the viral capsid and interaction with host cells. 2.2 Selection of target proteins The protein sequences of the PVY N Egypt strain were retrieved in FASTA format from the NCBI database. ( https://www.ncbi.nlm.nih.gov ). To obtain their 3D structures in PDB format, a search was conducted on the Protein Data Bank (PDB) ( https://www.rcsb.org/ ). For target proteins lacking experimental 3D structures, homology modeling was employed using tools such as SWISS-MODEL or Phyre2 to generate 3D models based on sequence similarity to known structures. The quality and accuracy of the modeled structures were assessed through validation techniques, including Ramachandran plot analysis, to ensure structural reliability. 2.3 Selection of bioactive compounds from turmeric and related phytochemicals A number of bioactive compounds-(Bisdemethoxycurcumin, Caffeic acid, Curcumin, Curcuminol, Curdione, Demethoxycurcumin, Isorhamnetin, Sinapic acid and Ribavirin as a control) known for their antiviral properties, were chosen based on previous studies. Their chemical structures were gained in 2D SDF style from the PubChem database ( https://pubchem.ncbi.nlm.nih.gov/ ). 2.4 Virtual screening of bioactive compounds A small compound library consisting of the selected bioactive compounds was created for virtual screening. PyRx software ( https://sourceforge.net/projects/pyrx/ ), which utilizes energy minimization and docking via the AutoDock Vina plugin, was employed for screening the compounds against the PVY replicase and coat protein. Compounds with lower binding energy values, suggesting stronger binding potential, were prioritized. The 2D structures were converted to 3D and optimized for energy minimization using Open Babel and Chem3D. Furthermore, the compounds were evaluated for drug-likeness and bioavailability by applying Lipinski's rule of five through tools like SwissADME [ 18 ]. 2.5 Molecular Docking The following steps were followed to conduct detailed docking simulations. The target proteins were preprocessed by removing water molecules and irrelevant ligands using PyMOL. Hydrogen atoms were added, and either Kollman or Gasteiger charges were assigned. Ligand energy minimization was performed using Open Babel or Chem3D to ensure geometrical stability for accurate docking. Molecular docking was carried out using CB-Dock and AutoDock Vina. Binding affinities (in kcal/mol) were recorded for each protein-ligand interaction. CB-Dock also enabled automatic identification of binding sites, which improved docking accuracy. 2.6 Visualization and Analysis Using Discovery Studio 2022 (BIOVIA, Dassault Systèmes, 2022), the docking results were analyzed and visualized to examine key interactions, including hydrogen bonds, hydrophobic interactions, and ionic interactions [ 30 ]. 3 Results 3.1 Physicochemical properties of ligands Data in Table (1) demonstrates the physicochemical properties of a series of ligands used in virtual screening, including molecular weight (MW), rotatable bonds (RB), and hydrogen bonding potential (acceptors and donors). These properties provide insights into the potential bioactivity, solubility, and drug-likeness of the compounds. The molecular weight of the compounds varies significantly. Curcuminol is the heaviest compound, with a molecular weight of 566.51 g/mol. In contrast, Caffeic acid and Sinapic acid are on the lower end, with molecular weights of 180.16 g/mol and 224.21 g/mol, respectively. Most of the compounds analyzed in this study fall within the typical molecular weight (MW) range of drug-like molecules, which is generally considered to be between 200 and 500 g/mol. This range is often associated with favorable pharmacokinetic properties, including good absorption and membrane permeability. Curcuminol, however, is an exception, exhibiting a molecular weight above this typical range. Higher molecular weight compounds can face challenges such as reduced bioavailability and limited cellular uptake, which may impact their overall therapeutic potential. Therefore, while curcuminol demonstrates promising binding interactions in silico, its pharmacokinetic properties warrant further investigation through in vitro and in vivo studies to fully assess its viability as an antiviral agent. The number of rotatable bonds among the compounds ranges from 1 in Curdione to 13 in Curcuminol, with the latter exhibiting the highest degree of molecular flexibility. This suggests that Curcuminol may possess greater conformational diversity. In contrast, compounds such as Curdione and Caffeic acid have only 1 or 2 rotatable bonds, indicating more rigid molecular structures. The variation in hydrogen bond acceptors (HBA) and hydrogen bond donors (HBD) is also notable. Curcuminol and Isorhamnetin exhibit the highest number of HBAs, with 12 and 7, respectively, whereas Curdione contains only 2 HBAs and no HBDs. Ribavirin, a well-known antiviral compound, has a molecular weight of 244.2 g/mol, 3 rotatable bonds, and a balanced hydrogen bonding profile, comprising 7 HBAs and 4 HBDs. This profile suggests that Ribavirin is relatively small in size, moderately flexible, and possesses favorable hydrogen bonding potential—features that may contribute to its antiviral efficacy. Curcumin, with a molecular weight of 368.38 g/mol, contains 8 rotatable bonds and 6 HBAs, making it somewhat larger and more flexible than Ribavirin. These properties may play a role in its biological activity. Similarly, Demethoxycurcumin exhibits comparable physicochemical characteristics, indicating its potential as a promising candidate for virtual screening and further antiviral investigation. 3.2 ADMET properties and toxicity profile of ligands The ADMET properties and toxicity profiles of the ligands used in virtual screening are critical in determining their pharmacokinetic behavior and potential therapeutic efficacy (Table 2 ). Data in this table summarizes essential ADMET features, such as gastrointestinal (GI) absorption, blood-brain barrier (BBB) permeability, cytochrome P450 (CYP) inhibition, and compliance with Lipinski’s rule of five, alongside their toxicity classification (Toxic or Non-Toxic, T/NT). GI absorption is a significant determinant of a compound’s bioavailability. Compounds with high GI absorption are generally expected to have favorable oral bioavailability. Most of the ligands (e.g., bisdemethoxycurcumin, Caffeic acid, curcumin, Curdione, demethoxycurcumin, isorhamnetin, Sinapic acid) are predicted to have high GI absorption, suggesting that they could be absorbed efficiently when administered orally. Curcuminol and ribavirin were predicted to have low gastrointestinal (GI) absorption, which may present challenges for their oral bioavailability. Low GI absorption often results in limited systemic exposure following oral administration, potentially reducing the therapeutic efficacy of these compounds. Ribavirin, despite its established antiviral use, is known to have variable oral bioavailability depending on formulation and dosage. For curcuminol, the low predicted absorption suggests that alternative delivery methods or formulation strategies might be necessary to enhance its bioavailability, such as nanoformulations or co-administration with absorption enhancers. These considerations highlight the importance of integrating pharmacokinetic profiling early in drug development to optimize candidate selection. Blood-brain barrier (BBB) permeability is a critical factor for compounds targeting central nervous system (CNS) disorders. Within this dataset, bisdemethoxycurcumin and Curdione are predicted to be BBB permeant, suggesting their potential to cross the blood-brain barrier and act on CNS-related diseases. In contrast, most other ligands, including Caffeic acid, Curcumin, and Demethoxycurcumin, are not expected to penetrate the BBB, indicating their suitability for treating peripheral conditions. Cytochrome P450 (CYP) enzymes play a pivotal role in drug metabolism, and inhibition of these enzymes can result in significant drug-drug interactions. Several compounds in this study are predicted to inhibit one or more CYP isoforms. Notably, bisdemethoxycurcumin and demethoxycurcumin inhibit multiple CYP enzymes such as CYP1A2, CYP2C9, and CYP3A4, which could pose risks of interactions if administered alongside other drugs metabolized by these pathways. Curcumin, isorhamnetin, and ribavirin specifically inhibit CYP3A4, an enzyme responsible for metabolizing a wide range of pharmaceuticals. Conversely, compounds like Caffeic acid, curcuminol, Curdione, Sinapic acid, and ribavirin do not significantly inhibit major CYP enzymes, potentially lowering the risk of adverse metabolic interactions. Lipinski’s "Rule of Five" remains a widely accepted criterion for evaluating the drug-likeness and oral bioavailability of compounds. The data indicate that most of the studied molecules, except for curcuminol, comply with Lipinski’s parameters (noted as "Yes" under Lipinski), suggesting favorable drug-like properties and potential oral bioavailability. Curcuminol, characterized by its high molecular weight (566.51 g/mol) and elevated hydrogen bonding capacity, violates Lipinski’s rule, implying potential challenges related to solubility and oral absorption. Table 1 Physicochemical properties of ligands used in virtual screening: molecular weight, rotatable bonds, and hydrogen bonding characteristics. Swiss ADMET Molecular weight (g/mol) No. rotatable bonds No. H-bond acceptors No. H-bond donors Bisdemethoxycurcumin 308.33 6 4 2 Caffeic acid 180.16 2 4 3 Curcumin 368.38 8 6 2 Curcuminol 566.51 13 12 3 Curdione 236.35 1 2 0 Demethoxycurcumin 338.35 7 5 2 Isorhamnetin 316.26 2 7 4 Sinapic acid 224.21 4 5 2 Ribavirin (Control) 244.20 3 7 4 Notes: ADMET: Absorption, Distribution, Metabolism, Excretion, and Toxicity. Table 2 ADMET properties and toxicity profile of ligands used in virtual screening: absorption, permeability, CYP inhibition, and Lipinski's rule. Swiss ADMET GI absorption BBB permeant CYP1A2 inhibitor CYP2C19 inhibitor CYP2C9 inhibitor CYP2D6 inhibitor CYP3A4 inhibitor Lipinski T or NT Bisdemethoxycurcumin High Yes Yes No Yes No Yes Yes T Caffeic acid High No No No No No No Yes NT Curcumin High No No No Yes No Yes Yes NT Curcuminol Low No No No No No No No T Curdione High Yes No No No No No Yes T Demethoxycurcumin High No Yes No Yes No Yes Yes T Isorhamnetin High No Yes No No Yes Yes Yes NT Sinapic acid High No No No No No No Yes NT Ribavirin (Control) Low No No No No No No Yes NT Notes: CYP: Cytochrome P450; ADMET: Absorption, Distribution, Metabolism, Excretion, and Toxicity; GI: Gastrointestinal; BBB: Blood-brain barrier; T: Toxic; and NT: Non Toxic. Toxicity assessments are crucial for determining the safety profile of candidate compounds. According to the data, curcuminol and Curdione are classified as toxic, whereas all other compounds—including the control, ribavirin—are deemed non-toxic. This finding indicates that despite promising ADMET characteristics, the potential toxicity of curcuminol and Curdione could limit their therapeutic applicability. 3.3 Virtual screening of ligand binding affinity Results presented in Table 3 and Figs. (2 and 3) summarize the virtual screening outcomes for ligand binding affinities and Root Mean Square Deviation (RMSD) values against three key proteins of the PVYN-Egypt strain: P1 protease, Helper Component Proteinase (HCPro), and Coat Protein (CP). Binding affinity is expressed in kcal/mol, with more negative values indicating stronger ligand-protein interactions. RMSD values are reported for both upper bound (ub) and lower bound (lb), reflecting the precision of the predicted ligand-protein complexes. Notably, all RMSD values are zero, indicating highly accurate docking predictions or minimal deviations from the initial ligand binding poses. The Potyvirus P1 protease (pfam01577) of PVY is a vital enzyme involved in polyprotein processing and viral replication. Among the tested ligands, binding affinities range from − 5.5 kcal/mol to − 7.1 kcal/mol, with Isorhamnetin demonstrating the strongest affinity at − 7.1 kcal/mol, highlighting its potential as a promising inhibitor of this critical viral enzyme. Table 3 Virtual screening of ligand binding affinity and root mean square deviation (RMSD) for PVY N -Egypt strain proteins: P1 protease, helper component proteinase, and coat protein. PVY proteins Ligands Binding Affinity RMSD/ub RMSD/lb P1 protease (pfam01577) Bisdemethoxycurcumin -6.4 0 0 Caffeic acid -5.7 0 0 Curcumin -6.4 0 0 Curcuminol -5.9 0 0 Curdione -6.1 0 0 Demethoxycurcumin -5.9 0 0 Isorhamnetin -7.1 0 0 Sinapic acid -5.5 0 0 Ribavirin(Control) -6.3 0 0 Helper component proteinase (pfam00851) Bisdemethoxycurcumin -6.4 0 0 Caffeic_acid -5.1 0 0 Curcumin -5.9 0 0 Curcuminol -6.2 0 0 Curdione -5.5 0 0 Demethoxycurcumin -6.4 0 0 Isorhamnetin -6.4 0 0 Sinapic acid -5 0 0 Ribavirin (Control) -5.8 0 0 Coat protein (pfam00767) Bisdemethoxycurcumin -6.5 0 0 Caffeic_acid -6.1 0 0 Curcumin -7.4 0 0 Curcuminol -6.3 0 0 Curdione -6.3 0 0 Demethoxycurcumin -6.5 0 0 Isorhamnetin -7.4 0 0 Sinapic acid -5.8 0 0 Ribavirin (Control) -6.6 0 0 Note: PVY N : Potato virus Y strain N-Egypt. Table 4 Docking scores for ligand interaction with PVY N -Egypt strain proteins: P1 protease, helper component proteinase, and coat protein. PVY proteins Ligand Docking Scores P1 protease (pfam01577) Bisdemethoxycurcumin -7.5 Curcumin -7.5 Isorhamnetin -7.3 Ribavirin (Control) -6.3 Helper component proteinase (pfam00851) Bisdemethoxycurcumin -6.6 Curcumin -6.3 Curcuminol -6.5 Demethoxycurcumin -6.3 Isorhamnetin -6.3 Ribavirin (Control) -5.5 Coat protein (pfam00767) Curcumin -7.2 Isorhamnetin -6.5 Ribavirin (Control) -6.3 Note: PVY N : Potato virus Y strain N-Egypt. Table 5 Detailed analysis of ligand interactions with PVY N P1 protease (pfam01577): amino acid binding sites and bonding types. Ligands Amino acids Sites Type of bonds Bisdemthoxycurcunin ARG E:3004 Pi-Anion & Pi-Alkyl ILE E:2874 Pi-Alkyl ARG F:2970 Conventional hydrogen GLN E:2873 Conventional hydrogen SER E:3003 Conventional hydrogen GLU F:2974 Pi-Anion PRO F:2975 Pi-Alkyl Curcumin ARG D:2970 Conventional hydrogen GLN C:2873 Conventional hydrogen SER C:3003 Conventional hydrogen GLU D:2974 Carbon hydrogen SER B:2848 Carbon hydrogen Pro D:2975 Pi-Alkyl ARG C:3004 Pi-Alkyl & Pi-Cation ILE C:2874 Pi-Alkyl Isorhamnetin SER I:3003 Conventional hydrogen GLN I:2873 Conventional hydrogen ILE I:2874 Pi-Alkyl GLU J:2974 Salt Bridge & Pi-Anion ARG I:3004 Pi-Alkyl & Alkyl Pro J:2975 Alkyl ILE H:2846 Pi-Alkyl Ribavirin GLU F:2974 Conventional hydrogen GLU M:2946 Conventional hydrogen PRO M:2943 Carbon hydrogen ASN M:2947 Conventional hydrogen & Conventional hydrogen ALA M:2892 Pi-Alkyl & Carbon hydrogen ALA M:2896 Pi-Sigma MET M:2895 Unfavorable acceptor-acceptor ASN F:2971 Unfavorable acceptor-acceptor Notes: PVY N : Potato virus Y strain N-Egypt; ARG: Arginine; ILE: Isoleucine; GLN: Glutamine; SER: Serine; GLU: Glutamic acid; Pro: Proline; ASN: Asparagine; ALA: Alanine; and MET: Methionine. Table 6 Binding interactions of ligands with the PVY N helper component proteinase (pfam00851): amino acid sites and bonding types. Ligands Amino acids Sites Type of bonds Bisdemthoxycurcunin LYS A:54 Pi-Alkyl SER A:42 Conventional hydrogen PHE A:43 Conventional hydrogen ARG A:27 Pi-Alkyl & Carbon hydrogen ILE A:28 Conventional hydrogen Curcumin ALA A:55 Pi-Alkyl LEU A:53 Pi-Alkyl HIS A:32 Pi-Pi T-Shaped VAL A:30 PI-Alky & Alkyl CYS A:37 Alkyl & Pi-Sulfur GLN A:35 Carbon Hydrogen GLN A:60 Conventional hydrogen LYS A:54 Amide-Pi Stacked & Alkyl Curcuminol GLN A:60 Conventional hydrogen & Conventional hydrogen LYS A:54 Conventional hydrogen & Pi-Alkyl ILE A:52 Conventional hydrogen TYR A:50 Conventional hydrogen CYS A:37 Pi-Alkyl VAL A:30 Alkyl & Pi-Alkyl PHE A:64 Pi-Sulfur LEU A:53 Pi-Alkyl ALA A:55 Pi-Alkyl Demethoxycurcumin PRO A:26 Conventional hydrogen ARG A:27 Pi-Alkyl, Pi-Alkyl, Conventional hydrogen, Conventional hydrogen Isorhamnetin ILE A:52 Alkyl THR A:47 Carbon Hydrogen ARG A:27 Conventional hydrogen. Pi-Alkyl, Alkyl, Unfavorable-Positive-Positive, Pi-Alkyl SER A:42 Unfavorable acceptor-acceptor PHE A:43 Carbon hydrogen LEU A:53 Unfavorable acceptor-acceptor LYS A:54 Alkyl, Carbon hydrogen Ribavirin PRO A:26 Unfavorable acceptor-acceptor LEU A:25 Conventional hydrogen ASP A:41 Conventional hydrogen & Carbon hydrogen ARG A:27 Pi-Alkyl THR A:47 Conventional hydrogen ALA A:55 Conventional hydrogen Notes: PVY N : Potato virus Y strain N-Egypt; LYS: Lysine; SER: Serine; PHE: Phenylalanine; ARG: Arginine; ILE: Isoleucine; ALA: Alanine; LEU: Leucine; HIS: Histidine; VAL: Valine; PRO: Proline; THR: Threonine; and ASP: Aspartic acid. Table 7 Ligand binding interactions with the PVY N coat protein (pfam00767): amino acid residues and bonding characteristics. Ligands Amino acids Sites Type of bonds Curcumin ARG A:55 Pi-Cation GLN A:140 Conventional hydrogen, Unfavorable Donor-Donor ASP A:91 Carbon Hydrogen GLY A:61 Conventional hydrogen, Conventional hydrogen LYS A:60 Conventional hydrogen HIS A:162 Pi-Alkyl Isorhamnetin ARG A:55 Conventional hydrogen ASP A:91 Conventional hydrogen Ribavirin ASN A:82 Conventional hydrogen THR A:86 Conventional hydrogen, Conventional hydrogen, Pi-lone Pair TRP A:118 Conventional hydrogen GLY A:130 Carbon Hydrogen Notes: PVY N : Potato virus Y strain N-Egypt; ARG: Arginine; GLN: Glutamine; ASP: Aspartic acid; GLY: Glycine; LYS: Lysine; HIS: Histidine; ASN: Asparagine; THR: Threonine; and TRP: Tryptophan. . This suggests that Isorhamnetin may be a promising candidate for further exploration in antiviral drug design targeting the P1 protease. Other ligands, such as Bisdemethoxycurcumin and Curcumin, also display strong binding affinities of -6.4 kcal/mol, aligning with previous findings that curcuminoids exhibit antiviral properties. The control compound Ribavirin (often used in antiviral research) exhibits a binding affinity of -6.3 kcal/mol, confirming its potential efficacy. The HCPro (pfam00851) is essential for virus transmission by aphids and aids in the viral replication cycle. The binding affinities for this protein span from − 5.0 kcal/mol to -6.4 kcal/mol, with Bisdemethoxycurcumin and Demethoxycurcumin showing the most favorable binding at -6.4 kcal/mol. These results align with studies suggesting that curcuminoids have broad-spectrum antiviral activity, including against plant viruses. Isorhamnetin, another compound showing high affinity at -6.4 kcal/mol, could also represent a promising candidate for inhibiting HCPro activity. Additionally, the control compound Ribavirin shows a slightly lower binding affinity of -5.8 kcal/mol, consistent with its known mechanism as an antiviral agent. The PVY N -Egypt CP (pfam00767) is responsible for the encapsidation of viral RNA, a crucial step for virus stability and transmission. The binding affinities for ligands range from − 5.8 kcal/mol to -7.4 kcal/mol, with Curcumin and Isorhamnetin exhibiting the most favorable binding at -7.4 kcal/mol. These results are consistent with previous works highlighting the antiviral potential of curcuminoids, which can disrupt viral capsid formation and viral RNA encapsidation. The control compound Ribavirin shows a binding affinity of -6.6 kcal/mol, which is consistent with its established antiviral activity. The RMSD values for the ligand-protein complexes are reported as 0 across all ligand-protein interactions in this dataset. This suggests that there were no significant deviations between the predicted and observed ligand conformations. While RMSD values close to zero may suggest highly precise docking simulations, it is important to recognize that such results can also reflect inherent limitations of the docking methodology employed. Specifically, zero or near-zero RMSD values may indicate that only initial docking poses were evaluated without further refinement or validation steps, which can limit the reliability of claims regarding binding accuracy. Therefore, these findings should be interpreted with caution, and complementary methods or experimental validation are recommended to confirm the predicted ligand-protein interactions. 3.4 Docking scores for ligand interaction with PVY N -Egypt strain proteins Data in Table (4) present the docking scores for various ligands interacting with three key proteins from the PVY N -Egypt strain: P1 protease, helper component proteinase, and coat protein. The docking scores, reported in kcal/mol, reflect the binding affinities of ligands to the target proteins, with more negative values indicating stronger binding. The P1 protease, essential for the cleavage of viral polyproteins, is a critical target for antiviral drug design. The docking scores for ligands interacting with this protein range from − 6.3 kcal/mol to -7.5 kcal/mol, with Bisdemethoxycurcumin and Curcumin showing the most favorable docking scores of -7.5 kcal/mol. Isorhamnetin also shows a relatively strong binding score of -7.3 kcal/mol, indicating its potential as an effective ligand against P1 protease. The control compound, Ribavirin, displayed a less favorable docking score of -6.3 kcal/mol, but still indicates significant interaction with the protein. These results suggest that curcumin derivatives and flavonoids such as Isorhamnetin may serve as promising antiviral agents for inhibiting P1 protease function. The docking scores for ligands binding to HCPro range from − 5.5 kcal/mol to -6.6 kcal/mol. Bisdemethoxycurcumin shows the highest docking score of -6.6 kcal/mol, followed by Curcuminol at -6.5 kcal/mol. Isorhamnetin also demonstrates a docking score of -6.3 kcal/mol. Ribavirin, the control compound, shows the lowest docking score of -5.5 kcal/mol, which is still noteworthy but suggests it is less effective in binding to HCPro compared to the other ligands. The CP of PVY is responsible for encapsidating the viral RNA, a critical process for the stability and transmission of the virus. The docking scores for the ligands binding to the Coat protein range from − 6.3 kcal/mol to -7.2 kcal/mol. Curcumin shows the strongest binding score at -7.2 kcal/mol. Isorhamnetin follows closely with a docking score of -6.5 kcal/mol. The control compound Ribavirin displayed a docking score of -6.3 kcal/mol, which, although lower, still suggests a moderate affinity for CP. 3.5 Detailed analysis of ligand interactions with PVY P1 protease Data in Table (5) and Figs. (2 & 3) demonstrate the analysis of ligand interactions with PVY P1 protease (pfam01577), providing a detailed understanding of the binding modes and interactions of various ligands to certain amino acid residues of the enzyme's active site. These interactions include various bond types such as Pi-Alkyl, Pi-Anion, hydrogen bonds, salt bridges, and unfavorable acceptor-acceptor interactions. These binding characteristics can influence the stability, specificity, and overall efficacy of ligand binding to the protease, which is critical for the design of therapeutic inhibitors targeting PVY P1 protease. Bisdemethoxycurcumin exhibits diverse binding types with the protease, including Pi-Anion, Pi-Alkyl, and conventional hydrogen bonds. Key residues involved in these interactions include ARG (E:3004), ILE (E:2874), ARG (F:2970), GLN (E:2873), SER (E:3003), GLU (F:2974), and PRO (F:2975). The presence of Pi-Anion and Pi-Alkyl interactions with ARG and ILE suggests strong aromatic interactions, which could enhance the establishment of the ligand in the protease's binding site, especially in hydrophobic regions. The hydrogen bonds with residues like GLN, SER, and ARG suggest that these interactions could contribute to the overall binding affinity by stabilizing the ligand in the active site. Curcumin shows a variety of interactions, including Pi-Alkyl, Pi-Cation, and hydrogen bonds with residues such as ARG (D:2970), GLN (C:2873), SER (C:3003), GLU (D:2974), PRO (D:2975), and ARG (C:3004). The Pi-Cation interaction between ARG (C:3004) and the ligand is significant as it enhances the binding stability in the active site. Pi-Alkyl interactions with ILE residues (such as ILE (C:2874)) further suggest that the ligand’s aromatic groups are well-positioned to interact with hydrophobic areas of the protease. The inclusion of hydrogen bonds at multiple sites (e.g., GLN, SER) likely contributes to the ligand's specificity and affinity for the protease, which is crucial for efficient inhibition. Isorhamnetin forms several key interactions, such as Pi-Alkyl, salt bridges, and hydrogen bonds with residues like SER (I:3003), GLN (I:2873), ILE (I:2874), GLU (J:2974), and ARG (I:3004). Salt bridge interactions with GLU (J:2974) are particularly significant, as salt bridges are known to enhance the stability of ligand-protein complexes by forming electrostatic interactions, which can provide a strong binding affinity. The hydrogen bonds with SER and GLN likely help to stabilize the ligand within the active site, increasing its specificity and binding affinity. Ribavirin interacts with several residues in the protease’s active site, including GLU (F:2974), GLU (M:2946), PRO (M:2943), ASN (M:2947), ALA (M:2892), MET (M:2895), and ASN (F:2971). Ribavirin exhibits various bond types, including Pi-Alkyl, hydrogen bonds, and unfavorable acceptor-acceptor interactions. The Pi-Alkyl interaction with ALA (M:2892) and Pi-Sigma interaction with ALA (M:2896) are significant for stabilizing the ligand in the hydrophobic pocket of the protease. The existence of untoward acceptor-acceptor interactions, particularly with MET (M:2895) and ASN (F:2971), suggests that ribavirin may experience steric hindrance or reduced binding affinity due to these unfavorable interactions. This could be a drawback in its effectiveness as an inhibitor of PVY P1 protease. 3.6 Binding interactions of ligands with the PVY helper component proteinase The analysis of ligand interactions with PVY helper component proteinase (pfam00851), as summarized in Table (6) and illustrated in Figs. (4 & 5), provides an in-depth view of the binding mechanisms and the types of bonds formed between the ligands and key amino acid residues in the enzyme’s active site. Understanding these interactions is essential for evaluating the potential inhibitory efficacy and designing optimized inhibitors. Bisdemethoxycurcumin primarily interacts with the protease through a combination of Pi-Alkyl, conventional hydrogen bonds, and carbon-hydrogen bonds. Key amino acids involved include LYS (A:54), SER (A:42), PHE (A:43), ARG (A:27), and ILE (A:28). Pi-Alkyl interactions with ARG (A:27) and LYS (A:54) suggest that aromatic rings of the ligand are positioned to interact with hydrophobic and electrostatic regions of the enzyme’s active site, stabilizing the ligand-protein complex and enhancing binding affinity. The presence of conventional hydrogen bonds with residues such as SER and ILE further supports the formation of a strong, stable complex, likely contributing to the ligand’s potency as a protease inhibitor. Curcumin forms a broad range of interactions, including Pi-Alkyl, Pi-Pi T-Shaped, Pi-Sulfur, and conventional hydrogen bonds. Notable binding sites include ALA (A:55), LEU (A:53), HIS (A:32), VAL (A:30), CYS (A:37), GLN (A:35), and LYS (A:54). The Pi-Pi T-Shaped interaction with HIS (A:32) suggests that the aromatic structure of curcumin may form a planar interaction with the Histidine side chain, stabilizing the binding. Pi-Sulfur interactions with CYS (A:37), as well as Amide-Pi Stacked and Pi-Alkyl interactions with LYS (A:54), indicate that the ligand is engaging in both hydrophobic and electrostatic interactions, enhancing the overall binding stability. The variety of binding interactions, including carbon-hydrogen bonds and alkyl interactions, suggests that curcumin has a strong binding profile that could contribute to effective inhibition of the protease. Curcuminol also forms a wide array of interactions, including Pi-Alkyl, conventional hydrogen bonds, Pi-Sulfur, and alkyl interactions. The key binding residues include GLN (A:60), LYS (A:54), ILE (A:52), TYR (A:50), CYS (A:37), and LEU (A:53). Pi-Alkyl interactions with LYS (A:54) and VAL (A:30) suggest that hydrophobic interactions between the aromatic rings of the ligand and these residues are critical for stabilizing the complex. The Pi-Sulfur interaction with PHE (A:64) indicates that sulfur-containing groups may participate in aromatic stacking interactions, further stabilizing the ligand’s binding within the active site. Hydrogen bonds at multiple sites (e.g., GLN (A:60) and LYS (A:54)) likely contribute to enhancing the ligand's affinity for the protease. Demethoxycurcumin primarily forms Pi-Alkyl, hydrogen bonds, and conventional hydrogen bonds with PRO (A:26) and ARG (A:27). The Pi-Alkyl interactions at ARG (A:27) indicate the potential for strong hydrophobic interactions, which may help anchor the ligand in the active site. The presence of conventional hydrogen bonds with PRO (A:26) suggests a stable binding orientation, which could be beneficial for maintaining the interaction with the protease. Isorhamnetin exhibits a mix of Pi-Alkyl, hydrogen bonds, alkyl interactions, and unfavorable acceptor-acceptor interactions. Significant binding residues include ILE (A:52), THR (A:47), ARG (A:27), SER (A:42), PHE (A:43), LEU (A:53), and LYS (A:54). Pi-Alkyl interactions with ARG (A:27) and ILE (A:52) suggest that the ligand’s aromatic rings are engaging in hydrophobic interactions with these key residues, stabilizing the complex. The unfavorable acceptor-acceptor interactions observed at SER (A:42) and LEU (A:53) may indicate some steric hindrance or a less favorable binding conformation, which could reduce the overall binding efficiency and effectiveness as an inhibitor. Ribavirin forms several key interactions, including Pi-Alkyl, conventional hydrogen bonds, and carbon-hydrogen bonds with PRO (A:26), LEU (A:25), ASP (A:41), ARG (A:27), THR (A:47), and ALA (A:55). The Pi-Alkyl interaction with ARG (A:27) and ALA (A:55) suggests that the ligand is interacting with hydrophobic regions in the enzyme’s active site, which could contribute to its binding stability. Conventional hydrogen bonds with ASP (A:41) and THR (A:47) provide additional stabilizing interactions, enhancing the ligand’s binding affinity. Curcumin, bisdemethoxycurcumin, and curcuminol exhibit a diverse set of interactions with the protease, including Pi-Alkyl, Pi-Pi T-Shaped, Pi-Sulfur, and hydrogen bonds, which suggest that these ligands are well-positioned to engage the enzyme in a stable and specific manner. The presence of Pi-Sulfur interactions with CYS (A:37) in curcumin and curcuminol highlights the potential for unique interaction profiles that could improve binding affinity. Demethoxycurcumin and ribavirin show more limited interaction profiles, which may influence their binding potency and specificity. However, ribavirin still shows some significant binding interactions, which could be optimized for better protease inhibition. Hydrogen bonding is a crucial interaction for ligand binding and specificity. Ligands such as curcumin and curcuminol form multiple hydrogen bonds with residues like GLN (A:35), GLN (A:60), and LYS (A:54), which contribute to their high binding affinity. Isorhamnetin, while forming several hydrogen bonds, also experiences unfavorable acceptor-acceptor interactions that may reduce its overall binding stability, which could limit its effectiveness. Isorhamnetin and ribavirin exhibit some unfavorable acceptor-acceptor interactions, which may hinder optimal binding to the protease and reduce their overall effectiveness as inhibitors. Isorhamnetin, in particular, may need structural modifications to overcome these interactions and enhance binding efficiency. 3.7 Ligand binding interactions with the PVY coat protein The ligand binding interactions with the PVY CP (pfam00767) are summarized in Table (7) and Fig. (6), providing insights into the types of interactions formed between the ligands and the key amino acid residues in the protein’s structure. These interactions, including Pi-Cation, hydrogen bonds, and carbon-hydrogen bonds, play a crucial role in the persistence and affinity of ligand binding, which is vital for the development of effective inhibitors. Curcumin forms various interactions, including Pi-Cation, conventional hydrogen bonds, carbon-hydrogen bonds, and unfavorable donor-donor interactions. The Pi-Cation interaction with ARG (A:55) suggests a strong aromatic interaction, which stabilizes binding in the hydrophobic pocket. Hydrogen bonds are formed with GLN (A:140), GLY (A:61), and LYS (A:60), enhancing the ligand’s affinity for the protein. Unfavorable donor-donor interactions with GLN (A:140) suggest some steric hindrance, potentially reducing binding efficiency. The Pi-Alkyl interaction with HIS (A:162) further stabilizes the ligand-protein complex. Isorhamnetin forms multiple hydrogen bonds with ARG (A:55) and ASP (A:91), suggesting that these interactions are important for maintaining the ligand’s position within the binding site, thereby enhancing its binding affinity. However, the ligand forms fewer interactions compared to curcumin, indicating a potentially less stable binding. Ribavirin forms hydrogen bonds with ASN (A:82), THR (A:86), TRP (A:118), and GLY (A:130). It also exhibits Pi-lone pair interactions with THR (A:86), suggesting non-covalent interactions that enhance binding specificity. Carbon-hydrogen bonds with GLY (A:130) further contribute to binding stability. Overall, ribavirin's interaction profile suggests stable binding, though potentially weaker or less specific compared to other ligands. 4 Discussion The analysis of the physicochemical properties of the ligands offers important insights into their potential bioactivity, pharmacokinetics, and overall drug-likeness. Molecular weight is a critical factor influencing absorption, distribution, metabolism, and excretion (ADME) characteristics. Generally, smaller molecules exhibit improved membrane permeability and absorption, whereas larger molecules often face challenges related to poor solubility and reduced bioavailability. Among the ligands evaluated, Curcuminol, with a molecular weight of 566.51 g/mol, is the heaviest, which may negatively impact its absorption and oral bioavailability. Conversely, compounds such as Caffeic acid and Sinapic acid, which possess lower molecular weights, are likely to demonstrate better absorption profiles. Most ligands fall within the typical molecular weight range for drug-like compounds (200–500 g/mol), with Curcuminol as the notable exception, suggesting potential limitations for its oral administration [ 19 ]. These findings align with established knowledge that smaller molecules generally achieve superior membrane permeability and absorption, while larger compounds may be hindered by poor solubility and permeability issues [ 20 ]. The number of rotatable bonds influences the flexibility of a molecule, which can have both positive and negative implications for binding to biological targets. A higher number of rotatable bonds can increase the conformational diversity of a molecule, potentially improving its ability to bind to a range of targets. However, excessive flexibility could lead to instability and reduced specificity. Curcuminol, with 13 rotatable bonds, is the most flexible molecule in the set, which could increase its potential for binding to various targets but might also compromise its stability. On the other hand, compounds like Curdione (1 RB) and Caffeic acid (2 RB) are more rigid, which may offer better specificity for well-defined targets, although it could limit their binding diversity [ 21 , 22 ]. The hydrogen bonding capacity of a compound influences its solubility and interaction with biomolecules. Compounds with a high number of HBA and donors (HBD) can exhibit strong interactions with biological targets, but excessive hydrogen bonding may reduce membrane permeability [ 23 ]. Curcuminol and isorhamnetin, with the highest number of HBA (12 and 7, respectively), may have strong interactions with the polar regions of biological targets. However, such compounds may also face challenges in terms of membrane permeability. Curdione, with only 2 HBA and no HBD, is less likely to engage in hydrogen bonding, potentially reducing its bioactivity but increasing its specificity. Ribavirin, with a balanced hydrogen bonding profile, could be seen as an optimized structure for maintaining bioactivity while potentially having favorable ADME properties [ 24 ]. The physicochemical and ADMET profiles of the tested ligands reveal significant insights into their potential as antiviral agents against the PVY N -Egypt strain. Curcuminol, despite its high molecular weight and flexibility, violates Lipinski’s rule and shows low gastrointestinal absorption, which may limit its oral bioavailability and clinical application, consistent with previous observations that large, flexible molecules often face bioavailability challenges [ 25 ]. In contrast, ligands like curcumin, bisdemethoxycurcumin, and isorhamnetin exhibit favorable drug-like properties with high GI absorption and compliance with Lipinski’s rule, highlighting their potential as orally active candidates [ 26 ]. The toxicity profiles further refine candidate selection, as compounds such as curdione and curcuminol show potential toxicity, warranting caution in further development [ 27 ]. Virtual screening results demonstrated strong binding affinities of curcuminoids and flavonoids to key viral proteins, with isorhamnetin and bisdemethoxycurcumin showing particularly promising interactions with the P1 protease and helper component proteinase, suggesting their role as potent inhibitors in viral replication and transmission processes [ 28 ]. The control drug ribavirin, despite moderate binding affinity, confirms the validity of the docking approach and underscores the improved efficacy of these natural ligands in targeting PVY proteins [ 29 ]. Detailed interaction analyses reveal that hydrogen bonding, Pi-Alkyl, and salt bridge formations are critical in ligand stabilization within the active sites, aligning with prior studies that emphasize the importance of multi-modal interactions for effective protease inhibition [ 30 , 31 ]. Moreover, the inability of most ligands to permeate the blood-brain barrier aligns with the peripheral targeting profile required for plant viral infections, reducing the risk of central nervous system side effects [ 32 ]. However, bisdemethoxycurcumin and curdione’s BBB permeability may open avenues for broader antiviral applications but require further toxicity assessment. Collectively, these findings suggest that the curcuminoids and flavonoids under study merit further in vitro and in vivo validation as potential antiviral agents, especially given their multifaceted interaction profiles and favorable ADMET characteristics, supporting the growing body of evidence on natural products as valuable scaffolds in antiviral drug discovery [ 33 , 34 ]. GI absorption is a critical determinant of oral bioavailability, as compounds with high GI absorption are generally absorbed more efficiently from the gastrointestinal tract. In this dataset, most compounds are predicted to have high GI absorption, which is a favorable characteristic for potential drug development. However, curcuminol and ribavirin, with predicted low GI absorption, could face challenges related to oral bioavailability. These compounds might experience poor intestinal permeability or high first-pass metabolism, which can limit their therapeutic effectiveness [ 35 ]. The ability of a compound to cross the blood-brain barrier (BBB) is critical for drugs targeting the CNS. In this dataset, bisdemethoxycurcumin and Curdione are predicted to be BBB permeant, suggesting their potential for treating CNS-related diseases. On the other hand, most other ligands, such as Caffeic acid, curcumin, and demethoxycurcumin, are not predicted to cross the BBB, suggesting they may be more effective for treating peripheral diseases [ 36 ]. Cytochrome P450 (CYP) enzymes are essential for the metabolism of numerous drugs, and their inhibition can result in potentially harmful drug-drug interactions. Bisdemethoxycurcumin and demethoxycurcumin are predicted to inhibit multiple CYP isoforms, raising concerns about significant interactions when co-administered with other therapeutics. Likewise, curcumin, isorhamnetin, and ribavirin inhibit CYP3A4, a key enzyme involved in the metabolism of a wide variety of drugs [ 37 , 38 ]. Therefore, the potential for CYP enzyme inhibition must be carefully evaluated during drug development, especially when these compounds are intended for use alongside other medications that depend on CYP-mediated metabolism [ 39 ]. Lipinski’s "Rule of Five" provides a widely accepted framework for assessing the drug-likeness of compounds, with adherence suggesting favorable oral bioavailability. In this analysis, most compounds, with the exception of curcuminol, conform to Lipinski’s criteria, indicating promising drug-like properties and a higher likelihood of oral absorption. Curcuminol, however, due to its large molecular weight and elevated hydrogen bonding capacity, violates Lipinski’s rule, which may pose challenges related to solubility and oral bioavailability [ 23 ]. Toxicity is a critical consideration in drug development, and compounds that are classified as toxic may pose risks for patient safety. In this dataset, curcuminol and Curdione are classified as toxic, suggesting that despite their promising ADMET properties, they may exhibit undesirable side effects that limit their therapeutic use. Conversely, compounds such as ribavirin, which are classified as non-toxic, may present fewer safety concerns, making them more suitable for further development. Therefore, toxicity must be considered alongside efficacy and ADMET properties to ensure the safe development of these compounds as potential therapeutics. In a summary, the ligands in this virtual screening dataset demonstrate varied ADMET properties, which can be linked to their pharmacological potential [ 40 ]. Bisdemethoxycurcumin, Curdione, and demethoxycurcumin show high GI absorption and favorable pharmacokinetic properties, though some of them are predicted to inhibit multiple CYP enzymes, raising concerns about drug-drug interactions. Curcumin, isorhamnetin, and ribavirin also show good absorption and drug-like properties but may exhibit interactions with CYP3A4. On the other hand, curcuminol exhibits poor GI absorption, does not comply with Lipinski's rule, and is classified as toxic, indicating that it may require substantial modifications to improve its drug-like properties and safety profile. Caffeic acid and Sinapic acid have high GI absorption and do not inhibit CYP enzymes, making them interesting candidates for further studies targeting peripheral diseases. The strong binding of Isorhamnetin to the P1 protease, with a binding affinity of -7.1 kcal/mol, highlights its potential as a lead compound for antiviral drug design targeting this key enzyme in the PVY N -Egypt strain. Curcuminoids like Bisdemethoxycurcumin and Curcumin also demonstrate promising binding affinities, which is consistent with their previously reported antiviral properties [ 10 , 11 ]. Curcuminoids have shown broad-spectrum activity against various viruses, including plant viruses, suggesting that they could be used to inhibit P1 protease activity in PVY [ 16 , 41 ]. Bisdemethoxycurcumin, Demethoxycurcumin, and Isorhamnetin show the most favorable binding to HCPro, with binding affinities of -6.4 kcal/mol. This is significant because HCPro plays an essential role in viral transmission and replication. The observed high binding affinities of curcuminoids and flavonoids like Isorhamnetin align with studies that report their broad-spectrum antiviral properties, particularly against plant viruses [ 16 , 41 , 42 ]. This suggests that these compounds may effectively inhibit HCPro activity, thereby reducing PVY replication and transmission. Curcumin and Isorhamnetin demonstrate the strongest binding affinities for the PVY N -Egypt coat protein at -7.4 kcal/mol, which could potentially interfere with viral capsid formation and RNA encapsidation, crucial steps for the virus's stability and transmission. The observed results are consistent with previous findings that curcuminoids can disrupt viral capsid formation [ 11 , 41 , 43 ], and Isorhamnetin, a flavonoid, has shown promising antiviral activity in several studies [ 44 ]. This suggests that both compounds could play a significant role in disrupting the viral lifecycle by targeting the coat protein. The RMSD (Root Mean Square Deviation) values of 0.0 observed across all ligand–protein complexes may initially suggest high accuracy in the docking predictions, indicating that the predicted binding poses are closely aligned with the reference conformations. However, such uniformly low RMSD values can also reflect methodological limitations, particularly when rigid docking protocols are employed. In this study, ligands were docked back into their native conformations without allowing for conformational flexibility or sampling of alternative binding modes. While this approach confirms pose reproducibility, it does not fully account for the dynamic nature of ligand–protein interactions in realistic biological environments [ 45 , 46 ]. We acknowledge this as a limitation of the current methodology and recommend that future studies incorporate flexible docking protocols or molecular dynamics simulations to enhance the predictive accuracy [ 47 ]. Accordingly, we have conducted a limited re-evaluation using flexible docking in this revision to support the reliability of our findings. Overall, the ligand binding affinities obtained in this study identify promising candidates for the development of antiviral agents against the PVYN-Egypt strain. Curcumin, Isorhamnetin, and Bisdemethoxycurcumin demonstrated strong binding across all three target proteins, underscoring their potential as broad-spectrum antiviral compounds. These findings are consistent with previous studies reporting the antiviral efficacy of curcumin derivatives and flavonoids, which have been shown to inhibit viral replication and disrupt key protein functions [ 10 , 11 , 44 ]. Additionally, Ribavirin, employed here as a standard antiviral control, exhibited comparatively strong binding affinities, reaffirming its established antiviral activity [ 24 ]. The docking results emphasize that curcumin derivatives and flavonoids—particularly Bisdemethoxycurcumin, Curcumin, and Isorhamnetin—possess strong affinity for critical proteins of the PVYN-Egypt strain. This aligns with the well-documented antiviral properties of curcuminoids, which are known to suppress viral proliferation by targeting essential viral enzymes and protein functions [ 45 – 47 ]. The high binding affinity of Isorhamnetin, a flavonoid, further supports the potential of flavonoids in antiviral drug discovery [ 48 , 49 ]. Additionally, Ribavirin, a well-known antiviral drug, exhibited docking scores in the moderate range across all three proteins. While its binding affinity was lower than that of curcumin derivatives and Isorhamnetin, Ribavirin's established antiviral activity [ 50 – 53 ], makes it a valuable control in this study. Bisdemethoxycurcumin, curcumin, and isorhamnetin show strong binding interactions with PVY P1 protease, particularly through a combination of Pi-Alkyl, Pi-Anion, hydrogen bonds, and Pi-Cation interactions. These ligands seem to have a well-established binding profile with significant contributions from both hydrophobic and polar interactions, which may contribute to their high binding affinity [ 54 – 56 ]. The salt bridge formation observed with GLU (J:2974) in isorhamnetin could indicate a more stable binding compared to other ligands, potentially making isorhamnetin a better candidate for inhibition [ 57 ]. Hydrogen bonding is a critical component of ligand-receptor interactions and significantly contributes to binding affinity and specificity. The ligands bisdemethoxycurcumin, curcumin, and isorhamnetin form multiple hydrogen bonds with residues like GLN, SER, and ARG, which help stabilize the ligand-receptor complex [ 48 – 50 ]. Ribavirin also forms hydrogen bonds, but the presence of unfavorable acceptor-acceptor interactions suggests that its binding affinity might be weaker or less stable compared to the other ligands. The unfavorable acceptor-acceptor interactions in ribavirin (with MET (M:2895) and ASN (F:2971) may reduce its binding efficiency and increase the likelihood of off-target effects or weaker inhibition. This suggests that ribavirin may require structural modifications to improve its binding profile and reduce unfavorable interactions [ 61 , 62 ]. Based on the detailed binding analysis, bisdemethoxycurcumin, curcumin, and isorhamnetin are strong candidates for further drug development targeting PVY P1 protease, given their favorable interaction profiles and strong binding affinities. These ligands could be optimized through structural modifications to improve potency, selectivity, and minimize toxicity [ 63 ]. Ribavirin, while having some beneficial interactions, may need structural optimization to overcome the unfavorable interactions and enhance its overall binding stability. Based on the diverse and stable interactions with key amino acids in the protease, curcumin, bisdemethoxycurcumin, and curcuminol appear to be strong candidates for further optimization and development as potent protease inhibitors. These ligands display a wide range of favorable interactions, indicating that they could effectively bind to and inhibit the PVY helper component proteinase. The variety of interactions, including Pi-Alkyl, Pi-Sulfur, Pi-Pi T-Shaped, and hydrogen bonding, suggests that these compounds are engaging in both hydrophobic and electrostatic interactions that contribute to their high binding affinity [ 64 , 65 ]. In particular, the Pi-Sulfur interactions with CYS (A:37) observed in curcumin and curcuminol highlight the potential for unique interaction profiles, which may improve the binding affinity and specificity for the protease. These interactions may provide these ligands with an advantage in terms of potency and selectivity for the target enzyme [ 66 ]. Moreover, the diversity of bonding types seen in bisdemethoxycurcumin and curcuminol-such as Pi-Alkyl, Pi-Pi T-Shaped, and hydrogen bonds-suggests that these compounds could engage the protease in a stable, multifaceted manner, likely enhancing their inhibitory potential [ 67 ]. While demethoxycurcumin and ribavirin show more limited interaction profiles, they still exhibit significant binding interactions, suggesting that their structures could be further optimized for better protease inhibition. The more limited interaction profiles may indicate that these compounds are less stable in the active site compared to curcumin derivatives, potentially reducing their potency as inhibitors. Structural modifications could improve these interactions and enhance the binding efficiency [ 56 , 68 ]. Isorhamnetin, despite forming several hydrogen bonds, exhibits unfavorable acceptor-acceptor interactions that may reduce its overall binding stability, thereby limiting its effectiveness as a protease inhibitor. These unfavorable interactions, especially with residues such as SER (A:42) and LEU (A:53), may result in steric hindrance or decreased affinity. Therefore, isorhamnetin could benefit from structural modifications aimed at overcoming these unfavorable interactions to enhance binding efficiency and improve its inhibitory potency [ 69 , 70 ]. Curcumin, bisdemethoxycurcumin, and curcuminol generally emerge as promising candidates for further development as protease inhibitors targeting the PVY helper component proteinase. Although isorhamnetin and ribavirin exhibit some potential, they may require structural optimization to mitigate unfavorable interactions and enhance their overall inhibitory efficacy [ 42 , 70 ]. Analysis of the binding interactions with the PVY coat protein highlights curcumin as the strongest candidate for development as a protease inhibitor against this target. The compound’s robust and stable binding affinity is likely driven by a diverse array of interactions, including Pi-Cation, Pi-Alkyl, and hydrogen bonds [ 67 , 71 ]. Notably, curcumin forms Pi-Cation interactions with ARG (A:55) and Pi-Alkyl interactions with HIS (A:162), indicating engagement through both hydrophobic and aromatic contacts, which contribute to a stable binding conformation. Furthermore, hydrogen bonds with residues such as GLN (A:140), GLY (A:61), and LYS (A:60) further reinforce the stability of the curcumin-protein complex, enhancing its affinity for the PVY coat protein [ 47 , 72 ]. However, an unfavorable donor-donor interaction with GLN (A:140) suggests possible steric clashes or electrostatic repulsion that could detract from curcumin’s binding efficiency at this site. Addressing this issue in future ligand optimization—potentially through structural modifications to reduce steric hindrance or electrostatic conflict—may improve binding potency [ 73 ]. Isorhamnetin, while promising as a ligand for the PVY coat protein, forms fewer interaction types compared to curcumin. It mainly establishes hydrogen bonds with key residues such as ARG (A:55) and ASP (A:91), suggesting effective binding, though possibly with lower affinity due to the more limited interaction profile [ 74 , 75 ]. Structural modifications aimed at enhancing the interaction profile—such as increasing hydrophobic contacts or introducing additional binding moieties—could improve the inhibitory potency and specificity of these compounds. Ribavirin forms stable hydrogen bonds with residues including ASN (A:82), THR (A:86), TRP (A:118), and GLY (A:130). Additionally, a Pi-lone pair interaction with THR (A:86) may contribute to binding specificity; however, ribavirin’s overall interaction profile is simpler compared to curcumin’s, which limits its binding affinity. Consequently, ribavirin may benefit from optimization to enhance its Pi-lone pair interactions and overall binding conformation [ 76 ]. Among the compounds studied, curcumin stands out as the most promising candidate for further development, owing to its diverse and stabilizing interactions, particularly the Pi-Cation and Pi-Alkyl interactions [ 77 , 78 ]. Isorhamnetin also shows potential for optimization, displaying favorable hydrogen bonding; yet, its affinity may be comparatively lower due to the narrower range of interaction types. Ribavirin, while forming stable interactions, is likely to require structural refinement to improve both its binding affinity and specificity for the PVY coat protein. Limitations While the docking results indicate promising binding interactions with RMSD values close to zero, it is important to recognize the inherent limitations of molecular docking simulations. Such ideal RMSD values may reflect methodological constraints, including limited sampling of ligand-protein conformations and reliance on static protein structures. Moreover, docking predictions are inherently computational and provide only a preliminary understanding of molecular interactions. Therefore, these findings should be interpreted as hypotheses that require subsequent experimental validation through in vitro and in vivo studies. Additionally, the complex dynamics of biological systems and potential off-target effects are not fully captured in silico, underscoring the need for cautious interpretation and further comprehensive investigations. Future Directions Building on the promising in silico findings of this study, future research should focus on experimental validation through in vitro assays to confirm the antiviral activity of the identified turmeric-derived compounds against PVY. Subsequently, in vivo studies will be essential to evaluate their efficacy and safety in plant models. Additionally, structural modifications of these bioactive molecules could be explored to enhance their binding affinity, bioavailability, and specificity. Investigating potential synergistic effects through combination therapies with existing antiviral agents may also provide more effective control strategies. Ultimately, integrating computational predictions with empirical data will facilitate the development of novel, targeted antiviral treatments for crop protection. 5 Conclusion These findings underscore the potential of curcumin derivatives and flavonoids as lead compounds in the development of antiviral agents against the PVY N -Egypt strain. Nonetheless, further in vitro and in vivo studies are necessary to validate their efficacy and safety. This study highlights turmeric-derived compounds, particularly curcuminoids, as promising antiviral candidates targeting key PVY proteins. Molecular docking analysis revealed that isorhamnetin exhibits strong affinity for the P1 protease, while curcumin and bisdemethoxycurcumin interact effectively with HCPro and CP, suggesting their potential to disrupt viral replication. ADMET profiling indicated favorable bioavailability and gastrointestinal absorption for most curcumin derivatives. However, curcuminol and ribavirin showed potential toxicity concerns. In summary, natural compounds such as curcuminoids and flavonoids-especially isorhamnetin-demonstrate significant promise as antiviral agents against PVY N -Egypt. These results support further experimental research for both agricultural protection and pharmaceutical development. Abbreviations 2D Two D structure 3D Three D structure ADMET Absorption, Distribution, Metabolism, Excretion, and Toxicity BBB Blood-brain barrier CNS Central nervous system CP Coat protein CYP Cytochrome P450 g/mol Gram/mole GI Gastrointestinal HBA Hydrogen bond acceptors HBD Hydrogen bond donors HCPro Helper component proteinase HIV Human Immunodeficiency Virus lb Lower bound MW Molecular weight NCBI National center for biotechnology information NT Non-Toxic PDB Protein Data Bank PVX Potato virus X PVY Potato Virus Y RB Rotatable bonds RMSD Root mean square deviation RNA Ribonucleic acid T Toxic TMV Tobacco mosaic virus ub Upper bound Declarations Ethics approval and consent to participate Ethical approval was not applicable for this study, as it involved only plant and microbial samples, which do not require review by a human or animal ethics committee Consent for Publication Availability of data and material Competing interests Funding The authors declare that no funds, grants, or other support were received during the preparation of this manuscript. Authors’ contributions Acknowledgements References Jones RA (2006) Control of plant virus diseases. Advances in Virus Research 67:205-244. ‏ https://doi.org/10.1016/S0065-3527(06)67006-1Get rights and content Quenouille J, Vassilakos N, Moury B (2013) Potato virus Y: A major crop pathogen that has provided major insights into the evolution of viral pathogenicity. Molecular plant pathology 14(5):439-452. ‏ https://doi.org/10.1111/mpp.12024 Nasr-Eldin MA, Othman BA, Megahed AA, et al (2018) Physiological, cytological and molecular analysis of PVY NTN -infected potato cultivars. Egyptian Journal of Experimental Biology (Botany) 14(1):171-185. https://www.ejmanager.com/mnstemps/15/151519330872.pdf?t=1554029194) Valkonen JP (2007) Viruses: economical losses and biotechnological potential. In Potato biology and biotechnology (pp. 619-641). Elsevier Science BV. ‏ https://doi.org/10.1016/B978-044451018-1/50070-1 Nasr-Eldin M, Messiha N, Othman B, et al (2019) Induction of potato systemic resistance against the Potato virus Y (PVY NTN ), using crude filtrates of Streptomyces spp. under greenhouse conditions. Egyptian Journal of Biological Pest Control 29(62):1-11. https://doi.org/10.1186/s41938-019-0165-1 Abd El-Aziz MH (2020) The importance of Potato virus Y Potyvirus. Journal of Plant Science and Phytopathology 4:009-015. ‏ dx.doi.org/10.29328/journal.jpsp.1001044 Adams MJ, Antoniw JF, Fauquet CM (2005) Molecular criteria for genus and species discrimination within the family Potyviridae . Archives of Virology 150(3):459-479. https://doi.org/10.1007/s00705-004-0440-6 Bekhit AED, Bekhit AA (2014) Natural antiviral compounds. Studies in Natural Products Chemistry 42: 195-228. https://doi.org/10.1016/B978-0-444-63281-4.00007-0 Anand P, Kunnumakkara AB, Newman RA, et al (2008) Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics 4(6):807-818. https://doi.org/10.1021/mp700113r Jennings MR, Parks RJ (2020) Curcumin as an antiviral agent. Viruses 12(11):1242. ‏ https://doi.org/10.3390/v12111242 Ardebili A, Pouriayevali MH, Aleshikh S, et al (2021) Antiviral therapeutic potential of curcumin: An update. Molecules 26(22):6994. ‏ https://doi.org/10.3390/molecules26226994 Pagadala NS, Syed K, Tuszynski J (2017) Software for molecular docking: A review. Biophysical Reviews 9(2):91-102. https://doi.org/10.1007/s12551-016-0247-1 Ferreira LG, Dos Santos RN, Oliva, G, et al (2015) Molecular docking and structure-based drug design strategies. Molecules 20(7):13384-13421. ‏ http://dx.doi.org/10.3390/molecules200713384 Morris GM, Lim-Wilby M (2008) Molecular docking. Molecular Modeling of Proteins 365-382. ‏ https://doi.org/10.1007/978-1-59745-177-2_19 Aseel DG, Rabie M, El-Far A, et al (2024) Antiviral properties and molecular docking studies of eco-friendly biosynthesized copper oxide nanoparticles against alfalfa mosaic virus. BMC Plant Biology 24(1):1089. ‏ https://doi.org/10.1186/s12870-024-05802-1 Behl T, Rocchetti G, Chadha S, et al (2021) Phytochemicals from plant foods as potential source of antiviral agents: An overview. Pharmaceuticals 14(4):381. ‏ https://doi.org/10.3390/ph14040381 Siddiqi MH, Siddiqi MZ, Kim SP (2019) Advances in molecular docking for antiviral drug discovery. Current Bioinformatics 14(3):240-254. https://doi.org/10.3390/md18110545 Daina A, Michielin O, Zoete V (2017) SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports 7(1):1-13. ‏ https://doi.org/10.1038/srep42717 Honorio MK, Moda LT, Andricopulo AD (2013) Pharmacokinetic properties and in silico ADME modeling in drug discovery. Medicinal Chemistry 9(2):163-176. ‏ http://dx.doi.org/10.2174/1573406411309020002 Veber DF, Johnson SR, Cheng HY, et al (2002) Molecular properties that influence the oral bioavailability of drug candidates. Journal of medicinal chemistry 45(12):2615-2623. https://doi.org/10.1021/jm020017n Maltarollo VG, Gertrudes JC, Oliveira PR, et al (2015) Applying machine learning techniques for ADME-Tox prediction: a review. Expert Opinion on Drug Metabolism and Toxicology 11(2):259-271. https://doi.org/10.1517/17425255.2015.980814 Alqahtani S (2017) In silico ADME-Tox modeling: progress and prospects. Expert opinion on drug metabolism and toxicology 13(11):1147-1158. ‏ https://doi.org/10.1080/17425255.2017.1389897 Graci JD, Cameron CE (2006) Mechanisms of action of ribavirin against distinct viruses. Reviews in Medical Virology 16(1):37-48. ‏ https://doi.org/10.1002/rmv.483 Lipinski CA, Lombardo F, Dominy BW, et al (2012) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 64:4-17. https://doi.org/10.1016/j.addr.2012.09.019 Ghose AK, Viswanadhan VN, Wendoloski JJ (1999) A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. Journal of Combinatorial Chemistry 1(1):55-68. https://doi.org/10.1021/cc9800071 Ekins S, Mestres J, Testa B (2007) In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. British Journal of Pharmacology 152(1):9-20. https://doi.org/10.1038/sj.bjp.0707305 De Clercq E (2006) Antiviral agents active against influenza A viruses. Nature Reviews Drug Discovery 5(12):1015-1025. https://doi.org/10.1038/nrd2175 Morris GM, Huey R, Lindstrom W, et al (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry 30(16):2785-2791. https://doi.org/10.1002/jcc.21256 Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2(1):3-14. https://doi.org/10.1602/neurorx.2.1.3 Newman DJ, Cragg GM (2016) Natural products as sources of new drugs from 1981 to 2014. Journal of Natural Products 79(3):629-661. https://doi.org/10.1021/acs.jnatprod.5b01055 Harvey AL, Edrada-Ebel R, Quinn RJ (2015) The re-emergence of natural products for drug discovery in the genomics era. Nature Reviews Drug Discovery 14(2):111-129. https://doi.org/10.1038/nrd4510 Vasconcelos T, Sarmento B, Costa P (2007) Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discovery Today 12(23-24):1068-1075. ‏ https://doi.org/10.1016/j.drudis.2007.09.005 Pardridge WM (2007) Blood–brain barrier delivery. Drug discovery today 12(1-2):54-61. ‏ https://doi.org/10.1016/j.drudis.2006.10.013 Choong CL, Islahudin F, Makmor-Bakry M, et al (2024). Effect of CYP3A5* 3, ABCC2 C-24T, and ABCC2 C3972T genetic polymorphisms on direct cost of kidney transplant recipients. Cureus 16(9): e69221. doi: 10.7759/cureus.69221 Zhang Y, Wang Z, Wang Y, et al (2024). CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms. PeerJ 12:p.e18636. https://peerj.com/articles/18636/ Scheen AJ (2011) Cytochrome P450-mediated cardiovascular drug interactions. Expert Opinion on Drug Metabolism and Toxicology 7(9):1065-1082. ‏ https://doi.org/10.1517/17425255.2011.586337 BIOVIA, Dassault Systèmes. (2022). Discovery Studio Visualizer (Version 2022). San Diego: Dassault Systèmes. Available at: https://www.3ds.com/products-services/biovia/products/molecular-modeling-simulation/biovia-discovery-studio/ Mathew D, Hsu WL (2018) Antiviral potential of curcumin. Journal of Functional Foods 40:692-699. ‏ https://doi.org/10.1016/j.jff.2017.12.017 Sharma A, Sharma T, Bhaskar R, et al (2024) Promising potential of curcumin and related compounds for antiviral drug discovery. Medicinal Chemistry 20(6):597-612. ‏ http://dx.doi.org/10.2174/0115734064277371240325105016 Hussain Y, Alam W, Ullah H, et al (2022) Antimicrobial potential of curcumin: therapeutic potential and challenges to clinical applications. Antibiotics 11(3):322. ‏ https://doi.org/10.3390/antibiotics11030322 Gong G, Guan YY, Zhang ZL, et al (2020) Isorhamnetin: A review of pharmacological effects. Biomedicine and Pharmacotherapy 128:110301. https://doi.org/10.1016/j.biopha.2020.110301 Lee WH, Loo CY, Bebawy M, et al (2013) Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21 st century. Current Neuropharmacology 11(4):338-378. ‏ https://doi.org/10.2174/1570159X11311040002 Zorofchian Moghadamtousi S, Abdul Kadir H, Hassandarvish P, et al (2014) A review on antibacterial, antiviral, and antifungal activity of Curcumin. BioMed Research International (1):186864. ‏ https://doi.org/10.1155/2014/186864 Oglah MK, Mustafa YF, Bashir MK, et al (2020) Curcumin and its derivatives: A review of their biological activities. Systematic Reviews in Pharmacy 11(3):472-481. ‏ https://doi.org/10.5530/srp.2020.3.60 Badshah SL, Faisal S, Muhammad A, et al (2021) Antiviral activities of flavonoids. Biomedicine and Pharmacotherapy 140:111596. ‏ https://doi.org/10.1016/j.biopha.2021.111596 Shahrajabian MH, Sun W, Cheng Q (2022) The importance of flavonoids and phytochemicals of medicinal plants with antiviral activities. Mini-Reviews in Organic Chemistry 19(3):293-318. ‏ http://dx.doi.org/10.2174/1570178618666210707161025 Naithani R, Huma LC, Holland LE, et al (2008) Antiviral activity of phytochemicals: a comprehensive review. Mini Reviews in Medicinal Chemistry 8(11):1106-1133. ‏ http://dx.doi.org/10.2174/138955708785909943 Komínek P, Komínková M, Jandová B (2016) Effect of repeated Ribavirin treatment on grapevine viruses. Acta Virologica 60(4):400-403. ‏ doi:10.4149/av_2016_04_400 Egerman RS (2019) New antiviral agents for treatment of hepatitis C. Clinical Obstetrics and Gynecology 62(4):823-834. ‏ https://doi.org/10.1097/grf.0000000000000457 Ninfali P, Antonelli A, Magnani M, et al (2020) Antiviral properties of flavonoids and delivery strategies . Nutrients 12(9):2534. ‏ https://doi.org/10.3390/nu12092534 Meng XY, Zhang HX, Mezei M, et al (2011). Molecular docking: a powerful approach for structure-based drug discovery. Current Computer-aided Drug Design 7(2):146-157. https://doi.org/10.2174/157340911795677602 Warren GL, Andrews CW, Capelli AM, et al (2006) A critical assessment of docking programs and scoring functions. Journal of medicinal chemistry, 49(20):5912-5931. https://doi.org/10.1021/jm050362n Kitchen DB, Decornez H, Furr JR, et al (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nature reviews Drug discovery 3(11):935-949. https://doi.org/10.1038/nrd1549 Gopal SM, Klumpers F, Herrmann C, et al (2017) Solvent effects on ligand binding to a serine protease. Physical Chemistry Chemical Physics 19(17):10753-10766. ‏ https://doi.org/10.1039/C6CP07899K Seow-Neng C, Abu Bakar N, Mahmood M, et al (2017) Alternative strategy in crop protection: protease inhibitors from turmeric. Crop Improvement: Sustainability Through Leading-Edge Technology 253-270. ‏ https://doi.org/10.1007/978-3-319-65079-1_11 Rizk MN, Ketta HA, Shabana YM (2024) Discovery of novel Trichoderma-based bioactive compounds for controlling potato virus Y based on molecular docking and molecular dynamics simulation techniques. Chemical and Biological Technologies in Agriculture 11(1):110. ‏ https://doi.org/10.1186/s40538-024-00629-2 Jiang S, Debnath AK (2000) A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. Biochemical and Biophysical Research Communications 270(1):153-157. ‏ https://doi.org/10.1006/bbrc.2000.2411 Ghosh AK, Chapsal BD, Weber IT, et al (2008) Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Accounts of Chemical Research 41(1):78-86. ‏ https://doi.org/10.1021/ar7001232 Agback P, Agback T (2018) Direct evidence of a low barrier hydrogen bond in the catalytic triad of a serine protease. Scientific Reports 8(1):10078. https://doi.org/10.1038/s41598-018-28441-7 Mulu A, Gajaa M, Woldekidan HB (2021) The impact of Curcumin derived polyphenols on the structure and flexibility COVID-19 main protease binding pocket: A molecular dynamics simulation study. Peer Journal 9:e11590. ‏ https://doi.org/10.7717/peerj.11590 Wang DP, Rizzo RC, Tirado-Rives J, et al (2001) Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs. Bioorganic and medicinal chemistry letters 11(21):2799-2802. ‏ https://doi.org/10.1016/S0960-894X(01)00510-8 Poongavanam V, Namasivayam V, Vanangamudi M, et al (2018) Integrative approaches in HIV‐1 non‐nucleoside reverse transcriptase inhibitor design. Wiley Interdisciplinary Reviews: Computational Molecular Science 8(1):e1328. ‏ https://doi.org/10.1002/wcms.1328 Bai L, Wei C, Zhang J, et al (2023) Design, synthesis, and anti-PVY biological activity of 1, 3, 5-triazine derivatives containing piperazine structure. International Journal of Molecular Sciences 24(9):8280. ‏ https://doi.org/10.3390/ijms24098280 Ekowati J, Widyowati R, Norhayati, et al (2023) Chemopreventive Practices in Traditional Medicine. In Herbal Medicine Phytochemistry : Applications and Trends (pp. 1-54). Cham: Springer International Publishing. ‏ https://doi.org/10.1007/978-3-031-21973-3_28-1 Liu X, Wang XJ (2020) Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. Journal of Genetics and Genomics 47(2):119-121. ‏ https://doi.org/10.1016/j.jgg.2020.02.001 Caughey B, Raymond LD, Raymond GJ, et al (2003) Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. Journal of Virology 77(9):5499-5502. ‏ https://doi.org/10.1128/jvi.77.9.5499-5502.2003 Du YN, Jia J, Yan JN, et al (2024) Non-covalent interactions between large yellow croaker ( Pseudosciaena crocea ) roe protein isolates and curcumin: Implications for enhanced curcumin delivery. Food Bioscience 60:104270. ‏ https://doi.org/10.1016/j.fbio.2024.104270 Ross IA (2024) Brassicaceae and Viral Diseases. In Plant-Based Therapeutics, Volume 2: The Brassicaceae Family (pp. 673-733). Cham: Springer Nature Switzerland. ‏ https://doi.org/10.1007/978-3-031-63681-3_14 Shahhamzehei N, Abdelfatah S, Efferth T (2022) In silico and in vitro identification of pan-coronaviral main protease inhibitors from a large natural product library. Pharmaceuticals 15(3):308. ‏ https://doi.org/10.3390/ph15030308 Fakih TM, Zainul R, Muchtaridi M. (2024) Molecular docking-based virtual screening and computational investigations of biomolecules ( Curcumin analogs ) as potential lead inhibitors for SARS-CoV-2 papain-like protease. Pharmacia 71:1-19. ‏ https://doi.org/10.3897/pharmacia.71.e123948 Helmy N, Afifi S, Othman B, El-Dougdoug K, et al (2023) Enhance potato resistance to Potato virus Y NTN using Curcumin nanoparticles: Inhibitory effects of curcumin nanoparticles on potato plants infected by Potato virus Y . Acta Fytotechnica et Zootechnica 26(3):1336-9245. https://orcid.org/0000-0003-2191-8446 Mbese Z, Khwaza V, Aderibigbe BA (2019) Curcumin and its derivatives as potential therapeutic agents in prostate, colon and breast cancers. Molecules 24(23):4386. ‏ https://doi.org/10.3390/molecules24234386 Elgorban AM, Debnath S, Bahkali AH, et al (2023) Exploring the potency of curcumin and phyto-compounds as inhibitors of tomato yellow leaf curl virus-sardinia's DNA-binding domain: a computational approach. Physiological and Molecular Plant Pathology 127:102098. ‏ https://doi.org/10.1016/j.pmpp.2023.102098 Sindhuja A, Vimalavathini RR, Kavimani S (2021) In silico docking studies of antiglycation activity of isorhamnetin on molecular proteins of advanced glycation end product (AGE) Pathway. Biomedical and Pharmacology Journal 14(4):2299-2307. ‏ https://dx.doi.org/10.13005/bpj/2331 Hidayati WN, Apriasti R, Addy HS, et al (2021) Distinguishing resistances of transgenic sugarcane generated from RNA interference and pathogen derived resistance approaches to combating Sugarcane mosaic virus . Indonesian Journal of Biotechnology 26(2):107114. https://pdfs.semanticscholar.org/1eef/dd0264d37a35ec7eaa0279dd026c40193003.pdf Li Y, Jiao J, Qi Y, et al (2021) Curcumin: A review of experimental studies and mechanisms related to periodontitis treatment. Journal of Periodontal Research 56(5):837-847. ‏ https://doi.org/10.1111/jre.12914 Sitohy M, Taha S, Abdel-Hamid M, et al (2021) Protecting potato plants against PVX and PVY viral infections by the application of native and chemically modified legume proteins. Journal of Plant Diseases and Protection 128:1101-1114. ‏ https://doi.org/10.1007/s41348-021-00448-9 Elshaer NA, El-Masry SS, Rabiee MS, et al (2025) In Silico prediction of the potential of some bioactive compounds from Licorice to target Banana bunchy top virus . Egyptian Journal of Phytopathology 53(1):194-224. https://doi.org/10.21608/ejp.2025.436169 Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 03 Sep, 2025 Read the published version in Beni-Suef University Journal of Basic and Applied Sciences → Version 1 posted Editorial decision: Revision requested 15 Aug, 2025 Reviewers agreed at journal 14 Aug, 2025 Reviews received at journal 12 Aug, 2025 Reviewers agreed at journal 12 Aug, 2025 Reviews received at journal 09 Aug, 2025 Reviewers agreed at journal 09 Aug, 2025 Reviewers agreed at journal 09 Aug, 2025 Reviews received at journal 09 Aug, 2025 Reviews received at journal 08 Aug, 2025 Reviewers agreed at journal 07 Aug, 2025 Reviewers agreed at journal 07 Aug, 2025 Reviewers agreed at journal 07 Aug, 2025 Reviewers agreed at journal 07 Aug, 2025 Reviewers agreed at journal 07 Aug, 2025 Reviewers agreed at journal 07 Aug, 2025 Reviewers invited by journal 07 Aug, 2025 Submission checks completed at journal 31 Jul, 2025 First submitted to journal 29 Jul, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7083267","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":498145879,"identity":"bf267567-5681-4c02-9917-173dc6e591b2","order_by":0,"name":"Allam Arafat Megahed","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAyklEQVRIiWNgGAWjYDACduYGKKOBgZk4LcyMUC08B0jWIpFApBb+ZsbGTzcY7uTzz3xj+LmgwoaBv707Aa8WicOMzdI5DM8sZ9zOMZaecSaNQeLM2Q34rTnM2ADUctjAQDrHQJq37TCDgUQufi3yQFt+g7VInjH+TZQWg8OMbRBbJHjMiLPFEKjFGqRF4kxamTXPmTQegn6RO958+DZIC3/74c23eSps5Pjbewl4HwQY/4FIDgMQyUNYOQKwPyBF9SgYBaNgFIwgAAAmfkC5pp5L9wAAAABJRU5ErkJggg==","orcid":"","institution":"Agricultural Botany Dept. (Plant Pathology), Faculty of Agriculture, Damietta University, New Damietta (P.B.34517), Egypt.","correspondingAuthor":true,"prefix":"","firstName":"Allam","middleName":"Arafat","lastName":"Megahed","suffix":""},{"id":498145880,"identity":"fc3866bf-32e4-4ae7-87c1-3d0b61c12de3","order_by":1,"name":"Alaa Barakat","email":"","orcid":"","institution":"Department of Agricultural Microbiology, Laboratory of Virology, Faculty of Agriculture, Ain Shams University, P.O. Box 68, Hadayek Shobra, Cairo, Egypt","correspondingAuthor":false,"prefix":"","firstName":"Alaa","middleName":"","lastName":"Barakat","suffix":""},{"id":498145881,"identity":"1d65cbc8-1e8a-4af9-a7c1-e818d69bcbe8","order_by":2,"name":"Ahmed Attya Embaby","email":"","orcid":"","institution":"Department of Agricultural Microbiology, Laboratory of Virology, Faculty of Agriculture, Ain Shams University, P.O. Box 68, Hadayek Shobra, Cairo, Egypt","correspondingAuthor":false,"prefix":"","firstName":"Ahmed","middleName":"Attya","lastName":"Embaby","suffix":""},{"id":498145882,"identity":"e9f55bc8-237d-4a03-a183-72a8e99b67c4","order_by":3,"name":"Sonya Hamouda Mohamed","email":"","orcid":"","institution":"Department of Agricultural Microbiology, Institute of Soil, Water and Environment Research Institute, Agricultural Research Center, P.O. Box 12619, Giza, Egypt","correspondingAuthor":false,"prefix":"","firstName":"Sonya","middleName":"Hamouda","lastName":"Mohamed","suffix":""},{"id":498145883,"identity":"a27dce0e-548e-418e-a5c3-4208ebbc7582","order_by":4,"name":"Atef Shoukry Sadik","email":"","orcid":"","institution":"Department of Agricultural Microbiology, Laboratory of Virology, Faculty of Agriculture, Ain Shams University, P.O. Box 68, Hadayek Shobra, Cairo, Egypt","correspondingAuthor":false,"prefix":"","firstName":"Atef","middleName":"Shoukry","lastName":"Sadik","suffix":""},{"id":498145884,"identity":"b862e79b-f414-4cd6-ad9f-1d86bfe9b7d4","order_by":5,"name":"Nashwa Ahmed Elshaer","email":"","orcid":"","institution":"Department of Plant Protection, Faculty of Agriculture, Zagazig University, 44511 Zagazig, Egypt","correspondingAuthor":false,"prefix":"","firstName":"Nashwa","middleName":"Ahmed","lastName":"Elshaer","suffix":""}],"badges":[],"createdAt":"2025-07-09 11:23:22","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7083267/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7083267/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s43088-025-00686-y","type":"published","date":"2025-09-03T15:57:27+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":88930291,"identity":"de1c5184-6da8-417c-9d81-1dbee6e4ec73","added_by":"auto","created_at":"2025-08-12 21:06:42","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":1186431,"visible":true,"origin":"","legend":"\u003cp\u003eAmino acid sequences of the potyvirus P1 protease, helper component proteinase, and coat protein from PVY\u003csup\u003eN\u003c/sup\u003e-Egypt strain (Accession No. AAM81207.1).\u003c/p\u003e","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-7083267/v1/233a8776e6ea540f92b3c320.png"},{"id":88930620,"identity":"0753f118-774b-4dbe-abaf-a43dd3464beb","added_by":"auto","created_at":"2025-08-12 21:22:42","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":672019,"visible":true,"origin":"","legend":"\u003cp\u003e2D and 3D structures of Ribavirin and Bisdemethoxycurcumin interactions with PVY P1 protease (pfam01577): amino acid binding sites and bonding types.\u003c/p\u003e","description":"","filename":"floatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-7083267/v1/4cf2d06d929e80faede68ed4.png"},{"id":88930297,"identity":"b46cbdb5-e210-4323-b136-9ed0c0f70fab","added_by":"auto","created_at":"2025-08-12 21:06:42","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":703844,"visible":true,"origin":"","legend":"\u003cp\u003e2D and 3D structures of Curcumin and Isorhamnetin interactions with PVY P1 protease (pfam01577): amino acid binding sites and bonding types.\u003c/p\u003e","description":"","filename":"floatimage6.png","url":"https://assets-eu.researchsquare.com/files/rs-7083267/v1/789da116f67a788d34daa32d.png"},{"id":88930621,"identity":"8af4c523-295e-402c-8a44-9f8662af5b81","added_by":"auto","created_at":"2025-08-12 21:22:42","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":135968,"visible":true,"origin":"","legend":"\u003cp\u003e2D and 3D structure of Ribavirin, Bisdemethoxycurcumin and Curcumin interactions with PVY-HC Pro (pfam00851): amino acid binding sites and bonding types.\u003c/p\u003e","description":"","filename":"floatimage8.png","url":"https://assets-eu.researchsquare.com/files/rs-7083267/v1/cb3a7274a54abf022ab8478f.png"},{"id":88930294,"identity":"ff920987-4751-4734-ab68-5c908a08135e","added_by":"auto","created_at":"2025-08-12 21:06:42","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":141208,"visible":true,"origin":"","legend":"\u003cp\u003e2D and 3D structure of Curcuminol, Demethoxycurcumin and Isorhamnetin interactions with PVY-HC Pro (pfam00851): amino acid binding sites and bonding types.\u003c/p\u003e","description":"","filename":"floatimage9.png","url":"https://assets-eu.researchsquare.com/files/rs-7083267/v1/1e5b9d3eb0ffdeae6af9cc4c.png"},{"id":88930912,"identity":"ec4794a8-26e6-4df7-9462-702446282997","added_by":"auto","created_at":"2025-08-12 21:30:42","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":884133,"visible":true,"origin":"","legend":"\u003cp\u003e2D and 3D structure of Ribavirin, Curcumin, and Isorhamnetin interactions with PVY-CP (pfam00767): amino acid binding sites and bonding types.\u003c/p\u003e","description":"","filename":"floatimage10.png","url":"https://assets-eu.researchsquare.com/files/rs-7083267/v1/5ba0b01c39a9d5f7822cbd04.png"},{"id":90827951,"identity":"6072400c-b8a8-42ed-ac17-36cf6bf9a502","added_by":"auto","created_at":"2025-09-08 16:03:56","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":5202403,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7083267/v1/8c1b1020-4d92-4536-aee9-ca0492988025.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Antiviral Activity of Turmeric (Curcuma longa) Against Potato Virus Y: In Silico Molecular Docking Analysis ","fulltext":[{"header":"1 Background","content":"\u003cp\u003ePotato Virus Y (PVY) is one of the most prevalent and economically damaging viruses affecting potato crops worldwide effectively conveys the importance of the study. It belongs to the \u003cem\u003ePotyvirus\u003c/em\u003e genus and is primarily transmitted by aphids. PVY infection can lead to a variety of symptoms, including mosaics, leaf curling, and stunting, ultimately resulting in reduced yield and quality of potatoes [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. The virus is a major contributor to significant yield losses, particularly in temperate regions where it is considered endemic. Infected potato plants commonly display a range of symptoms, including mosaic leaf patterns, leaf curling, and discoloration of tubers. These symptoms not only reduce overall crop yield but also compromise the quality and marketability of the harvested produce. In severely affected fields, yield losses can reach up to 30%, resulting in considerable economic impact. Financial burdens are further amplified by the increased reliance on pesticides, elevated disease management expenses, and the loss of tubers that meet commercial standards [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. In Europe and North America, losses associated with Potato virus Y (PVY) amount to millions of dollars each year, representing a major constraint on potato production and profitability [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. In Egypt-one of the leading potato producers in the Middle East and North Africa (MENA) region-PVY poses a serious threat to sustainable cultivation. Potatoes rank among the country's most valuable agricultural export commodities, and reports of PVY infections have been on the rise, especially in the Nile Delta region, where much of Egypt\u0026rsquo;s potato farming is concentrated [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. The virus not only affects yield but also diminishes the market value of the tubers, as symptoms reduce their quality and appearance, making them unsuitable for export. The economic burden in Egypt is further compounded by the lack of efficient control measures and the limited availability of resistant potato varieties.\u003c/p\u003e\u003cp\u003eGiven these challenges, the adoption of alternative control strategies-particularly plant-derived antiviral agents-has become increasingly vital to protect Egypt\u0026rsquo;s potato industry. At present, the management of PVY largely relies on chemical treatments, which raises significant concerns regarding environmental impact and the potential development of resistant viral strains [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. As a result, there is growing interest in exploring more sustainable and effective solutions, including the application of natural, plant-based compounds for combating viral infections in crops [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Among these, curcumin\u0026mdash;the principal bioactive compound in \u003cem\u003eCurcuma longa\u003c/em\u003e (turmeric)\u0026mdash;has attracted considerable attention due to its broad spectrum of biological activities, including antiviral, antibacterial, and anticancer properties [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. Curcumin, the bioactive component of \u003cem\u003eCurcuma longa\u003c/em\u003e (turmeric), has attracted significant attention due to its broad antiviral efficacy against several viruses, including HIV, Hepatitis B, and Influenza. This efficacy is primarily attributed to its ability to interfere with viral entry, replication, and modulation of the host immune response [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Molecular docking is a computational method frequently employed in drug development and structural biology to predict interactions between two molecules, typically a target protein and a small bioactive ligand [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. This approach entails positioning the ligand within the active or binding site of a target protein and assessing the interaction's strength and specificity using scoring functions. These functions take into account key factors such as binding affinity, hydrogen bonding, hydrophobic interactions, and steric compatibility [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. Molecular docking offers valuable insights into the molecular mechanisms underlying ligand\u0026ndash;protein interactions, facilitating the identification of potential inhibitors or modulators for therapeutic or biotechnological use [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. It is especially beneficial in \u003cem\u003ein silico\u003c/em\u003e studies, enabling efficient virtual screening and optimization of candidate compounds prior to experimental validation [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eMolecular docking has emerged as a powerful tool in the study of plant viruses, particularly in the development of antiviral agents aimed at controlling viral plant diseases. This computational technique enables researchers to investigate the interactions between key viral proteins\u0026mdash;critical for processes such as replication, movement, and host infection\u0026mdash;and potential inhibitory compounds derived from either synthetic sources or natural products [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. By targeting essential viral elements, including RNA-dependent RNA polymerases, coat proteins, and helicases, molecular docking facilitates the identification of molecules capable of interfering with the viral life cycle [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. This approach has proven especially useful in evaluating bioactive compounds from medicinal plants, many of which exhibit notable antiviral properties. For example, docking studies have been used to examine the binding of phytochemicals to the coat proteins of Tobacco mosaic virus (TMV) and Potato virus X (PVX), offering valuable insights into their potential to disrupt viral assembly or reduce infectivity [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Through high-throughput virtual screening and structural refinement, molecular docking significantly accelerates the discovery of environmentally friendly, plant-based antiviral agents to help reduce crop losses caused by plant viruses.\u003c/p\u003e\u003cp\u003eRecent advancements in in silico molecular docking investigations have introduced new insights into the interactions between bioactive compounds and viral proteins [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. These computational approaches allow investigators to deduce the binding affinity and molecular interactions between compounds and target viral proteins, offering valuable insights into their antiviral potential [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. In the context of PVY, exploring curcumin's binding interactions with key viral proteins may provide a novel strategy for managing PVY infections in potatoes. As Egypt continues to face significant challenges from PVY, the development of integrated pest management strategies and the exploration of natural antiviral agents, such as curcumin, are becoming increasingly critical. This study aims to investigate the in silico molecular docking interactions between curcumin and key PVY proteins, evaluating its potential as a natural antiviral agent against this economically devastating virus.\u003c/p\u003e"},{"header":"2 Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\u003ch2\u003e2.1 Target proteins of PVY\u003csup\u003eN\u003c/sup\u003e-Egypt strain\u003c/h2\u003e\u003cp\u003eTo ensure clarity and uniformity throughout the manuscript, all compound names (e.g., bisdemethoxycurcumin, demethoxycurcumin, isorhamnetin) have been consistently formatted in lowercase, following standard scientific nomenclature conventions. The target proteins selected in this study include P1 protease, helper component proteinase (HCPro), and coat protein (CP). Each protein plays a crucial role in the replication cycle of Potato Virus Y (PVY). P1 protease is involved in processing the viral polyprotein, HCPro acts as a suppressor of gene silencing and assists in viral movement, while the coat protein is essential for viral assembly and transmission. The amino acid sequences of three key proteins from Potato virus Y strain N-Egypt (Accession No. AAM81207) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e) are provided. These proteins include: a) Potyvirus P1 Protease (pfam01577): This protease is involved in the processing of viral polyproteins. The sequence spans amino acids 1\u0026ndash;200, with functional domains associated with viral replication and processing. b) Helper Component Proteinase (pfam00851): This protein is essential for virus transmission by aphids and functions a decisive work in the replication cycle. The sequence spans amino acids 1-421, with conserved regions associated with proteinase activity and aphid transmission. c) Potyvirus Coat Protein (pfam00767): The coat protein encapsulates the viral RNA, enabling viral stability and transmission. The sequence spans amino acids 1-241, containing key domains involved in the formation of the viral capsid and interaction with host cells.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec4\" class=\"Section2\"\u003e\u003ch2\u003e2.2 Selection of target proteins\u003c/h2\u003e\u003cp\u003eThe protein sequences of the PVY\u003csup\u003eN\u003c/sup\u003e Egypt strain were retrieved in FASTA format from the NCBI database. (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.ncbi.nlm.nih.gov\u003c/span\u003e\u003cspan address=\"https://www.ncbi.nlm.nih.gov\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e). To obtain their 3D structures in PDB format, a search was conducted on the Protein Data Bank (PDB) (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.rcsb.org/\u003c/span\u003e\u003cspan address=\"https://www.rcsb.org/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e). For target proteins lacking experimental 3D structures, homology modeling was employed using tools such as SWISS-MODEL or Phyre2 to generate 3D models based on sequence similarity to known structures. The quality and accuracy of the modeled structures were assessed through validation techniques, including Ramachandran plot analysis, to ensure structural reliability.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec5\" class=\"Section2\"\u003e\u003ch2\u003e2.3 Selection of bioactive compounds from turmeric and related phytochemicals\u003c/h2\u003e\u003cp\u003eA number of bioactive compounds-(Bisdemethoxycurcumin, Caffeic acid, Curcumin, Curcuminol, Curdione, Demethoxycurcumin, Isorhamnetin, Sinapic acid and Ribavirin as a control) known for their antiviral properties, were chosen based on previous studies. Their chemical structures were gained in 2D SDF style from the PubChem database (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://pubchem.ncbi.nlm.nih.gov/\u003c/span\u003e\u003cspan address=\"https://pubchem.ncbi.nlm.nih.gov/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e).\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec6\" class=\"Section2\"\u003e\u003ch2\u003e2.4 Virtual screening of bioactive compounds\u003c/h2\u003e\u003cp\u003eA small compound library consisting of the selected bioactive compounds was created for virtual screening. PyRx software (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://sourceforge.net/projects/pyrx/\u003c/span\u003e\u003cspan address=\"https://sourceforge.net/projects/pyrx/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e), which utilizes energy minimization and docking via the AutoDock Vina plugin, was employed for screening the compounds against the PVY replicase and coat protein. Compounds with lower binding energy values, suggesting stronger binding potential, were prioritized. The 2D structures were converted to 3D and optimized for energy minimization using Open Babel and Chem3D. Furthermore, the compounds were evaluated for drug-likeness and bioavailability by applying Lipinski's rule of five through tools like SwissADME [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e\u003ch2\u003e2.5 Molecular Docking\u003c/h2\u003e\u003cp\u003eThe following steps were followed to conduct detailed docking simulations. The target proteins were preprocessed by removing water molecules and irrelevant ligands using PyMOL. Hydrogen atoms were added, and either Kollman or Gasteiger charges were assigned. Ligand energy minimization was performed using Open Babel or Chem3D to ensure geometrical stability for accurate docking. Molecular docking was carried out using CB-Dock and AutoDock Vina. Binding affinities (in kcal/mol) were recorded for each protein-ligand interaction. CB-Dock also enabled automatic identification of binding sites, which improved docking accuracy.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e\u003ch2\u003e2.6 Visualization and Analysis\u003c/h2\u003e\u003cp\u003eUsing \u003cem\u003eDiscovery Studio 2022\u003c/em\u003e (BIOVIA, Dassault Syst\u0026egrave;mes, 2022), the docking results were analyzed and visualized to examine key interactions, including hydrogen bonds, hydrophobic interactions, and ionic interactions [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e].\u003c/p\u003e\u003c/div\u003e"},{"header":"3 Results","content":"\u003cdiv id=\"Sec10\" class=\"Section2\"\u003e\u003ch2\u003e3.1 Physicochemical properties of ligands\u003c/h2\u003e\u003cp\u003eData in Table\u0026nbsp;(1) demonstrates the physicochemical properties of a series of ligands used in virtual screening, including molecular weight (MW), rotatable bonds (RB), and hydrogen bonding potential (acceptors and donors). These properties provide insights into the potential bioactivity, solubility, and drug-likeness of the compounds. The molecular weight of the compounds varies significantly. Curcuminol is the heaviest compound, with a molecular weight of 566.51 g/mol. In contrast, Caffeic acid and Sinapic acid are on the lower end, with molecular weights of 180.16 g/mol and 224.21 g/mol, respectively. Most of the compounds analyzed in this study fall within the typical molecular weight (MW) range of drug-like molecules, which is generally considered to be between 200 and 500 g/mol. This range is often associated with favorable pharmacokinetic properties, including good absorption and membrane permeability. Curcuminol, however, is an exception, exhibiting a molecular weight above this typical range. Higher molecular weight compounds can face challenges such as reduced bioavailability and limited cellular uptake, which may impact their overall therapeutic potential. Therefore, while curcuminol demonstrates promising binding interactions in silico, its pharmacokinetic properties warrant further investigation through in vitro and in vivo studies to fully assess its viability as an antiviral agent.\u003c/p\u003e\u003cp\u003eThe number of rotatable bonds among the compounds ranges from 1 in Curdione to 13 in Curcuminol, with the latter exhibiting the highest degree of molecular flexibility. This suggests that Curcuminol may possess greater conformational diversity. In contrast, compounds such as Curdione and Caffeic acid have only 1 or 2 rotatable bonds, indicating more rigid molecular structures. The variation in hydrogen bond acceptors (HBA) and hydrogen bond donors (HBD) is also notable. Curcuminol and Isorhamnetin exhibit the highest number of HBAs, with 12 and 7, respectively, whereas Curdione contains only 2 HBAs and no HBDs. Ribavirin, a well-known antiviral compound, has a molecular weight of 244.2 g/mol, 3 rotatable bonds, and a balanced hydrogen bonding profile, comprising 7 HBAs and 4 HBDs. This profile suggests that Ribavirin is relatively small in size, moderately flexible, and possesses favorable hydrogen bonding potential\u0026mdash;features that may contribute to its antiviral efficacy. Curcumin, with a molecular weight of 368.38 g/mol, contains 8 rotatable bonds and 6 HBAs, making it somewhat larger and more flexible than Ribavirin. These properties may play a role in its biological activity. Similarly, Demethoxycurcumin exhibits comparable physicochemical characteristics, indicating its potential as a promising candidate for virtual screening and further antiviral investigation.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec11\" class=\"Section2\"\u003e\u003ch2\u003e3.2 ADMET properties and toxicity profile of ligands\u003c/h2\u003e\u003cp\u003eThe ADMET properties and toxicity profiles of the ligands used in virtual screening are critical in determining their pharmacokinetic behavior and potential therapeutic efficacy (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). Data in this table summarizes essential ADMET features, such as gastrointestinal (GI) absorption, blood-brain barrier (BBB) permeability, cytochrome P450 (CYP) inhibition, and compliance with Lipinski\u0026rsquo;s rule of five, alongside their toxicity classification (Toxic or Non-Toxic, T/NT). GI absorption is a significant determinant of a compound\u0026rsquo;s bioavailability. Compounds with high GI absorption are generally expected to have favorable oral bioavailability. Most of the ligands (e.g., bisdemethoxycurcumin, Caffeic acid, curcumin, Curdione, demethoxycurcumin, isorhamnetin, Sinapic acid) are predicted to have high GI absorption, suggesting that they could be absorbed efficiently when administered orally. Curcuminol and ribavirin were predicted to have low gastrointestinal (GI) absorption, which may present challenges for their oral bioavailability. Low GI absorption often results in limited systemic exposure following oral administration, potentially reducing the therapeutic efficacy of these compounds. Ribavirin, despite its established antiviral use, is known to have variable oral bioavailability depending on formulation and dosage. For curcuminol, the low predicted absorption suggests that alternative delivery methods or formulation strategies might be necessary to enhance its bioavailability, such as nanoformulations or co-administration with absorption enhancers. These considerations highlight the importance of integrating pharmacokinetic profiling early in drug development to optimize candidate selection. Blood-brain barrier (BBB) permeability is a critical factor for compounds targeting central nervous system (CNS) disorders. Within this dataset, bisdemethoxycurcumin and Curdione are predicted to be BBB permeant, suggesting their potential to cross the blood-brain barrier and act on CNS-related diseases. In contrast, most other ligands, including Caffeic acid, Curcumin, and Demethoxycurcumin, are not expected to penetrate the BBB, indicating their suitability for treating peripheral conditions. Cytochrome P450 (CYP) enzymes play a pivotal role in drug metabolism, and inhibition of these enzymes can result in significant drug-drug interactions. Several compounds in this study are predicted to inhibit one or more CYP isoforms. Notably, bisdemethoxycurcumin and demethoxycurcumin inhibit multiple CYP enzymes such as CYP1A2, CYP2C9, and CYP3A4, which could pose risks of interactions if administered alongside other drugs metabolized by these pathways. Curcumin, isorhamnetin, and ribavirin specifically inhibit CYP3A4, an enzyme responsible for metabolizing a wide range of pharmaceuticals. Conversely, compounds like Caffeic acid, curcuminol, Curdione, Sinapic acid, and ribavirin do not significantly inhibit major CYP enzymes, potentially lowering the risk of adverse metabolic interactions. Lipinski\u0026rsquo;s \"Rule of Five\" remains a widely accepted criterion for evaluating the drug-likeness and oral bioavailability of compounds. The data indicate that most of the studied molecules, except for curcuminol, comply with Lipinski\u0026rsquo;s parameters (noted as \"Yes\" under Lipinski), suggesting favorable drug-like properties and potential oral bioavailability. Curcuminol, characterized by its high molecular weight (566.51 g/mol) and elevated hydrogen bonding capacity, violates Lipinski\u0026rsquo;s rule, implying potential challenges related to solubility and oral absorption.\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003ePhysicochemical properties of ligands used in virtual screening: molecular weight, rotatable bonds, and hydrogen bonding characteristics.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"5\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eSwiss ADMET\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eMolecular weight (g/mol)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eNo. rotatable\u003c/p\u003e\u003cp\u003ebonds\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eNo. H-bond acceptors\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003eNo. H-bond donors\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eBisdemethoxycurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e\u003cp\u003e308.33\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e6\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e4\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e2\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCaffeic acid\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e\u003cp\u003e180.16\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e2\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e4\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e3\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e\u003cp\u003e368.38\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e8\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e6\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e2\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCurcuminol\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e\u003cp\u003e566.51\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e13\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e12\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e3\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCurdione\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e\u003cp\u003e236.35\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e2\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eDemethoxycurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e\u003cp\u003e338.35\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e7\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e5\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e2\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eIsorhamnetin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e\u003cp\u003e316.26\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e2\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e7\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e4\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eSinapic acid\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e\u003cp\u003e224.21\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e4\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e5\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e2\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eRibavirin (Control)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e\u003cp\u003e244.20\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e3\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e7\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e4\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"5\"\u003eNotes: ADMET: Absorption, Distribution, Metabolism, Excretion, and Toxicity.\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eADMET properties and toxicity profile of ligands used in virtual screening: absorption, permeability, CYP inhibition, and Lipinski's rule.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"10\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eSwiss ADMET\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGI absorption\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eBBB permeant\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eCYP1A2 inhibitor\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003eCYP2C19 inhibitor\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c6\"\u003e\u003cp\u003eCYP2C9 inhibitor\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c7\"\u003e\u003cp\u003eCYP2D6 inhibitor\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c8\"\u003e\u003cp\u003eCYP3A4 inhibitor\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c9\"\u003e\u003cp\u003eLipinski\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c10\"\u003e\u003cp\u003eT or NT\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eBisdemethoxycurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHigh\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003eT\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCaffeic acid\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHigh\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003eNT\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHigh\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003eNT\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCurcuminol\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eLow\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003eT\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCurdione\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHigh\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003eT\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eDemethoxycurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHigh\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003eT\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eIsorhamnetin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHigh\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003eNT\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eSinapic acid\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHigh\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003eNT\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eRibavirin (Control)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eLow\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003eNT\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"10\"\u003eNotes: CYP: Cytochrome P450; ADMET: Absorption, Distribution, Metabolism, Excretion, and Toxicity; GI: Gastrointestinal; BBB: Blood-brain barrier; T: Toxic; and NT: Non Toxic.\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003eToxicity assessments are crucial for determining the safety profile of candidate compounds. According to the data, curcuminol and Curdione are classified as toxic, whereas all other compounds\u0026mdash;including the control, ribavirin\u0026mdash;are deemed non-toxic. This finding indicates that despite promising ADMET characteristics, the potential toxicity of curcuminol and Curdione could limit their therapeutic applicability.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec12\" class=\"Section2\"\u003e\u003ch2\u003e3.3 Virtual screening of ligand binding affinity\u003c/h2\u003e\u003cp\u003eResults presented in Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e and Figs.\u0026nbsp;(2 and 3) summarize the virtual screening outcomes for ligand binding affinities and Root Mean Square Deviation (RMSD) values against three key proteins of the PVYN-Egypt strain: P1 protease, Helper Component Proteinase (HCPro), and Coat Protein (CP). Binding affinity is expressed in kcal/mol, with more negative values indicating stronger ligand-protein interactions. RMSD values are reported for both upper bound (ub) and lower bound (lb), reflecting the precision of the predicted ligand-protein complexes. Notably, all RMSD values are zero, indicating highly accurate docking predictions or minimal deviations from the initial ligand binding poses. The Potyvirus P1 protease (pfam01577) of PVY is a vital enzyme involved in polyprotein processing and viral replication. Among the tested ligands, binding affinities range from \u0026minus;\u0026thinsp;5.5 kcal/mol to \u0026minus;\u0026thinsp;7.1 kcal/mol, with Isorhamnetin demonstrating the strongest affinity at \u0026minus;\u0026thinsp;7.1 kcal/mol, highlighting its potential as a promising inhibitor of this critical viral enzyme.\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eVirtual screening of ligand binding affinity and root mean square deviation (RMSD) for PVY\u003csup\u003eN\u003c/sup\u003e-Egypt strain proteins: P1 protease, helper component proteinase, and coat protein.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"5\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePVY proteins\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eLigands\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eBinding Affinity\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eRMSD/ub\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003eRMSD/lb\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"8\" rowspan=\"9\"\u003e\u003cp\u003eP1 protease (pfam01577)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eBisdemethoxycurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-6.4\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCaffeic acid\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-5.7\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-6.4\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCurcuminol\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-5.9\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCurdione\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-6.1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eDemethoxycurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-5.9\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eIsorhamnetin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-7.1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eSinapic acid\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-5.5\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eRibavirin(Control)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-6.3\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"8\" rowspan=\"9\"\u003e\u003cp\u003eHelper component proteinase (pfam00851)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eBisdemethoxycurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-6.4\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCaffeic_acid\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-5.1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-5.9\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCurcuminol\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-6.2\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCurdione\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-5.5\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eDemethoxycurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-6.4\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eIsorhamnetin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-6.4\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eSinapic acid\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-5\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eRibavirin (Control)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-5.8\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"8\" rowspan=\"9\"\u003e\u003cp\u003eCoat protein (pfam00767)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eBisdemethoxycurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-6.5\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCaffeic_acid\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-6.1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-7.4\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCurcuminol\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-6.3\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCurdione\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-6.3\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eDemethoxycurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-6.5\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eIsorhamnetin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-7.4\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eSinapic acid\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-5.8\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eRibavirin (Control)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e-6.6\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e\u003cp\u003e0\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"5\"\u003eNote: PVY\u003csup\u003eN\u003c/sup\u003e: Potato virus Y strain N-Egypt.\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eDocking scores for ligand interaction with PVY\u003csup\u003eN\u003c/sup\u003e-Egypt strain proteins: P1 protease, helper component proteinase, and coat protein.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"3\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePVY proteins\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eLigand\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eDocking Scores\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e\u003cp\u003eP1 protease (pfam01577)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eBisdemethoxycurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e-7.5\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e-7.5\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eIsorhamnetin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e-7.3\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eRibavirin (Control)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e-6.3\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"5\" rowspan=\"6\"\u003e\u003cp\u003eHelper component proteinase (pfam00851)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eBisdemethoxycurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e-6.6\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e-6.3\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCurcuminol\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e-6.5\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eDemethoxycurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e-6.3\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eIsorhamnetin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e-6.3\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eRibavirin (Control)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e-5.5\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e\u003cp\u003eCoat protein (pfam00767)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e-7.2\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eIsorhamnetin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e-6.5\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eRibavirin (Control)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e\u003cp\u003e-6.3\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"3\"\u003eNote: PVY\u003csup\u003eN\u003c/sup\u003e: Potato virus Y strain N-Egypt.\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab5\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 5\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eDetailed analysis of ligand interactions with PVY\u003csup\u003eN\u003c/sup\u003e P1 protease (pfam01577): amino acid binding sites and bonding types.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"4\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eLigands\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eAmino acids\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eSites\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eType of bonds\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"6\" rowspan=\"7\"\u003e\u003cp\u003eBisdemthoxycurcunin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eARG\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eE:3004\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Anion \u0026amp; Pi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eILE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eE:2874\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eARG\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eF:2970\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGLN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eE:2873\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eSER\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eE:3003\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGLU\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eF:2974\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Anion\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePRO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eF:2975\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"7\" rowspan=\"8\"\u003e\u003cp\u003eCurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eARG\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eD:2970\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGLN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eC:2873\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eSER\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eC:3003\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGLU\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eD:2974\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eCarbon hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eSER\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eB:2848\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eCarbon hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePro\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eD:2975\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eARG\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eC:3004\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl \u0026amp; Pi-Cation\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eILE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eC:2874\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"6\" rowspan=\"7\"\u003e\u003cp\u003eIsorhamnetin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eSER\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eI:3003\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGLN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eI:2873\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eILE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eI:2874\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGLU\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eJ:2974\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eSalt Bridge \u0026amp; Pi-Anion\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eARG\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eI:3004\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl \u0026amp; Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePro\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eJ:2975\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eAlkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eILE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eH:2846\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"7\" rowspan=\"8\"\u003e\u003cp\u003eRibavirin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGLU\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eF:2974\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGLU\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eM:2946\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePRO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eM:2943\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eCarbon hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eASN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eM:2947\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen \u0026amp; Conventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eALA\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eM:2892\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl \u0026amp; Carbon hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eALA\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eM:2896\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Sigma\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eMET\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eM:2895\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eUnfavorable acceptor-acceptor\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eASN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eF:2971\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eUnfavorable acceptor-acceptor\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"4\"\u003eNotes: PVY\u003csup\u003eN\u003c/sup\u003e: Potato virus Y strain N-Egypt; ARG: Arginine; ILE: Isoleucine; GLN: Glutamine; SER: Serine; GLU: Glutamic acid; Pro: Proline; ASN: Asparagine; ALA: Alanine; and MET: Methionine.\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab6\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 6\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eBinding interactions of ligands with the PVY\u003csup\u003eN\u003c/sup\u003e helper component proteinase (pfam00851): amino acid sites and bonding types.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"4\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eLigands\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eAmino acids\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eSites\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eType of bonds\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"4\" rowspan=\"5\"\u003e\u003cp\u003eBisdemthoxycurcunin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eLYS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:54\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eSER\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:42\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePHE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:43\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eARG\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:27\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl \u0026amp; Carbon hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eILE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:28\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"7\" rowspan=\"8\"\u003e\u003cp\u003eCurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eALA\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:55\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eLEU\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:53\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHIS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:32\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Pi T-Shaped\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eVAL\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:30\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePI-Alky \u0026amp; Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCYS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:37\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eAlkyl \u0026amp; Pi-Sulfur\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGLN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:35\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eCarbon Hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGLN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:60\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eLYS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:54\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eAmide-Pi Stacked \u0026amp; Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"8\" rowspan=\"9\"\u003e\u003cp\u003eCurcuminol\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGLN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:60\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen \u0026amp; Conventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eLYS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:54\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen \u0026amp; Pi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eILE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:52\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eTYR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:50\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCYS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:37\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eVAL\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:30\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eAlkyl \u0026amp; Pi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePHE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:64\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Sulfur\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eLEU\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:53\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eALA\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:55\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eDemethoxycurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePRO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:26\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eARG\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:27\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl, Pi-Alkyl, Conventional hydrogen, Conventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"6\" rowspan=\"7\"\u003e\u003cp\u003eIsorhamnetin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eILE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:52\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eAlkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eTHR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:47\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eCarbon Hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eARG\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:27\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen. Pi-Alkyl, Alkyl, Unfavorable-Positive-Positive, Pi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eSER\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:42\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eUnfavorable acceptor-acceptor\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePHE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:43\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eCarbon hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eLEU\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:53\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eUnfavorable acceptor-acceptor\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eLYS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:54\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eAlkyl, Carbon hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"5\" rowspan=\"6\"\u003e\u003cp\u003eRibavirin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ePRO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:26\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eUnfavorable acceptor-acceptor\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eLEU\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:25\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eASP\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:41\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen \u0026amp; Carbon hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eARG\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:27\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eTHR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:47\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eALA\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:55\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"4\"\u003eNotes: PVY\u003csup\u003eN\u003c/sup\u003e: Potato virus Y strain N-Egypt; LYS: Lysine; SER: Serine; PHE: Phenylalanine; ARG: Arginine; ILE: Isoleucine; ALA: Alanine; LEU: Leucine; HIS: Histidine; VAL: Valine; PRO: Proline; THR: Threonine; and ASP: Aspartic acid.\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab7\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 7\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eLigand binding interactions with the PVY\u003csup\u003eN\u003c/sup\u003e coat protein (pfam00767): amino acid residues and bonding characteristics.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"4\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eLigands\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eAmino acids\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eSites\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eType of bonds\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"5\" rowspan=\"6\"\u003e\u003cp\u003eCurcumin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eARG\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:55\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Cation\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGLN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:140\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen, Unfavorable Donor-Donor\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eASP\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:91\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eCarbon Hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGLY\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:61\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen, Conventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eLYS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:60\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eHIS\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:162\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003ePi-Alkyl\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eIsorhamnetin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eARG\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:55\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eASP\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:91\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e\u003cp\u003eRibavirin\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eASN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:82\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eTHR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:86\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen, Conventional hydrogen, Pi-lone Pair\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eTRP\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:118\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eConventional hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eGLY\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003eA:130\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003eCarbon Hydrogen\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003ctfoot\u003e\u003ctr\u003e\u003ctd colspan=\"4\"\u003eNotes: PVY\u003csup\u003eN\u003c/sup\u003e: Potato virus Y strain N-Egypt; ARG: Arginine; GLN: Glutamine; ASP: Aspartic acid; GLY: Glycine; LYS: Lysine; HIS: Histidine; ASN: Asparagine; THR: Threonine; and TRP: Tryptophan.\u003c/td\u003e\u003c/tr\u003e\u003c/tfoot\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e. This suggests that Isorhamnetin may be a promising candidate for further exploration in antiviral drug design targeting the P1 protease. Other ligands, such as Bisdemethoxycurcumin and Curcumin, also display strong binding affinities of -6.4 kcal/mol, aligning with previous findings that curcuminoids exhibit antiviral properties. The control compound Ribavirin (often used in antiviral research) exhibits a binding affinity of -6.3 kcal/mol, confirming its potential efficacy. The HCPro (pfam00851) is essential for virus transmission by aphids and aids in the viral replication cycle. The binding affinities for this protein span from \u0026minus;\u0026thinsp;5.0 kcal/mol to -6.4 kcal/mol, with Bisdemethoxycurcumin and Demethoxycurcumin showing the most favorable binding at -6.4 kcal/mol. These results align with studies suggesting that curcuminoids have broad-spectrum antiviral activity, including against plant viruses. Isorhamnetin, another compound showing high affinity at -6.4 kcal/mol, could also represent a promising candidate for inhibiting HCPro activity. Additionally, the control compound Ribavirin shows a slightly lower binding affinity of -5.8 kcal/mol, consistent with its known mechanism as an antiviral agent. The PVY\u003csup\u003eN\u003c/sup\u003e-Egypt CP (pfam00767) is responsible for the encapsidation of viral RNA, a crucial step for virus stability and transmission. The binding affinities for ligands range from \u0026minus;\u0026thinsp;5.8 kcal/mol to -7.4 kcal/mol, with Curcumin and Isorhamnetin exhibiting the most favorable binding at -7.4 kcal/mol. These results are consistent with previous works highlighting the antiviral potential of curcuminoids, which can disrupt viral capsid formation and viral RNA encapsidation. The control compound Ribavirin shows a binding affinity of -6.6 kcal/mol, which is consistent with its established antiviral activity. The RMSD values for the ligand-protein complexes are reported as 0 across all ligand-protein interactions in this dataset. This suggests that there were no significant deviations between the predicted and observed ligand conformations. While RMSD values close to zero may suggest highly precise docking simulations, it is important to recognize that such results can also reflect inherent limitations of the docking methodology employed. Specifically, zero or near-zero RMSD values may indicate that only initial docking poses were evaluated without further refinement or validation steps, which can limit the reliability of claims regarding binding accuracy. Therefore, these findings should be interpreted with caution, and complementary methods or experimental validation are recommended to confirm the predicted ligand-protein interactions.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec13\" class=\"Section2\"\u003e\u003ch2\u003e3.4 Docking scores for ligand interaction with PVY\u003csup\u003eN\u003c/sup\u003e-Egypt strain proteins\u003c/h2\u003e\u003cp\u003eData in Table\u0026nbsp;(4) present the docking scores for various ligands interacting with three key proteins from the PVY\u003csup\u003eN\u003c/sup\u003e-Egypt strain: P1 protease, helper component proteinase, and coat protein. The docking scores, reported in kcal/mol, reflect the binding affinities of ligands to the target proteins, with more negative values indicating stronger binding. The P1 protease, essential for the cleavage of viral polyproteins, is a critical target for antiviral drug design. The docking scores for ligands interacting with this protein range from \u0026minus;\u0026thinsp;6.3 kcal/mol to -7.5 kcal/mol, with Bisdemethoxycurcumin and Curcumin showing the most favorable docking scores of -7.5 kcal/mol. Isorhamnetin also shows a relatively strong binding score of -7.3 kcal/mol, indicating its potential as an effective ligand against P1 protease. The control compound, Ribavirin, displayed a less favorable docking score of -6.3 kcal/mol, but still indicates significant interaction with the protein. These results suggest that curcumin derivatives and flavonoids such as Isorhamnetin may serve as promising antiviral agents for inhibiting P1 protease function. The docking scores for ligands binding to HCPro range from \u0026minus;\u0026thinsp;5.5 kcal/mol to -6.6 kcal/mol. Bisdemethoxycurcumin shows the highest docking score of -6.6 kcal/mol, followed by Curcuminol at -6.5 kcal/mol. Isorhamnetin also demonstrates a docking score of -6.3 kcal/mol. Ribavirin, the control compound, shows the lowest docking score of -5.5 kcal/mol, which is still noteworthy but suggests it is less effective in binding to HCPro compared to the other ligands. The CP of PVY is responsible for encapsidating the viral RNA, a critical process for the stability and transmission of the virus. The docking scores for the ligands binding to the Coat protein range from \u0026minus;\u0026thinsp;6.3 kcal/mol to -7.2 kcal/mol. Curcumin shows the strongest binding score at -7.2 kcal/mol. Isorhamnetin follows closely with a docking score of -6.5 kcal/mol. The control compound Ribavirin displayed a docking score of -6.3 kcal/mol, which, although lower, still suggests a moderate affinity for CP.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec14\" class=\"Section2\"\u003e\u003ch2\u003e3.5 Detailed analysis of ligand interactions with PVY P1 protease\u003c/h2\u003e\u003cp\u003eData in Table\u0026nbsp;(5) and Figs.\u0026nbsp;(2 \u0026amp; 3) demonstrate the analysis of ligand interactions with PVY P1 protease (pfam01577), providing a detailed understanding of the binding modes and interactions of various ligands to certain amino acid residues of the enzyme's active site. These interactions include various bond types such as Pi-Alkyl, Pi-Anion, hydrogen bonds, salt bridges, and unfavorable acceptor-acceptor interactions. These binding characteristics can influence the stability, specificity, and overall efficacy of ligand binding to the protease, which is critical for the design of therapeutic inhibitors targeting PVY P1 protease. Bisdemethoxycurcumin exhibits diverse binding types with the protease, including Pi-Anion, Pi-Alkyl, and conventional hydrogen bonds. Key residues involved in these interactions include ARG (E:3004), ILE (E:2874), ARG (F:2970), GLN (E:2873), SER (E:3003), GLU (F:2974), and PRO (F:2975). The presence of Pi-Anion and Pi-Alkyl interactions with ARG and ILE suggests strong aromatic interactions, which could enhance the establishment of the ligand in the protease's binding site, especially in hydrophobic regions. The hydrogen bonds with residues like GLN, SER, and ARG suggest that these interactions could contribute to the overall binding affinity by stabilizing the ligand in the active site. Curcumin shows a variety of interactions, including Pi-Alkyl, Pi-Cation, and hydrogen bonds with residues such as ARG (D:2970), GLN (C:2873), SER (C:3003), GLU (D:2974), PRO (D:2975), and ARG (C:3004). The Pi-Cation interaction between ARG (C:3004) and the ligand is significant as it enhances the binding stability in the active site. Pi-Alkyl interactions with ILE residues (such as ILE (C:2874)) further suggest that the ligand\u0026rsquo;s aromatic groups are well-positioned to interact with hydrophobic areas of the protease. The inclusion of hydrogen bonds at multiple sites (e.g., GLN, SER) likely contributes to the ligand's specificity and affinity for the protease, which is crucial for efficient inhibition. Isorhamnetin forms several key interactions, such as Pi-Alkyl, salt bridges, and hydrogen bonds with residues like SER (I:3003), GLN (I:2873), ILE (I:2874), GLU (J:2974), and ARG (I:3004). Salt bridge interactions with GLU (J:2974) are particularly significant, as salt bridges are known to enhance the stability of ligand-protein complexes by forming electrostatic interactions, which can provide a strong binding affinity. The hydrogen bonds with SER and GLN likely help to stabilize the ligand within the active site, increasing its specificity and binding affinity. Ribavirin interacts with several residues in the protease\u0026rsquo;s active site, including GLU (F:2974), GLU (M:2946), PRO (M:2943), ASN (M:2947), ALA (M:2892), MET (M:2895), and ASN (F:2971). Ribavirin exhibits various bond types, including Pi-Alkyl, hydrogen bonds, and unfavorable acceptor-acceptor interactions. The Pi-Alkyl interaction with ALA (M:2892) and Pi-Sigma interaction with ALA (M:2896) are significant for stabilizing the ligand in the hydrophobic pocket of the protease. The existence of untoward acceptor-acceptor interactions, particularly with MET (M:2895) and ASN (F:2971), suggests that ribavirin may experience steric hindrance or reduced binding affinity due to these unfavorable interactions. This could be a drawback in its effectiveness as an inhibitor of PVY P1 protease.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec15\" class=\"Section2\"\u003e\u003ch2\u003e3.6 Binding interactions of ligands with the PVY helper component proteinase\u003c/h2\u003e\u003cp\u003eThe analysis of ligand interactions with PVY helper component proteinase (pfam00851), as summarized in Table\u0026nbsp;(6) and illustrated in Figs.\u0026nbsp;(4 \u0026amp; 5), provides an in-depth view of the binding mechanisms and the types of bonds formed between the ligands and key amino acid residues in the enzyme\u0026rsquo;s active site. Understanding these interactions is essential for evaluating the potential inhibitory efficacy and designing optimized inhibitors. Bisdemethoxycurcumin primarily interacts with the protease through a combination of Pi-Alkyl, conventional hydrogen bonds, and carbon-hydrogen bonds. Key amino acids involved include LYS (A:54), SER (A:42), PHE (A:43), ARG (A:27), and ILE (A:28). Pi-Alkyl interactions with ARG (A:27) and LYS (A:54) suggest that aromatic rings of the ligand are positioned to interact with hydrophobic and electrostatic regions of the enzyme\u0026rsquo;s active site, stabilizing the ligand-protein complex and enhancing binding affinity. The presence of conventional hydrogen bonds with residues such as SER and ILE further supports the formation of a strong, stable complex, likely contributing to the ligand\u0026rsquo;s potency as a protease inhibitor. Curcumin forms a broad range of interactions, including Pi-Alkyl, Pi-Pi T-Shaped, Pi-Sulfur, and conventional hydrogen bonds. Notable binding sites include ALA (A:55), LEU (A:53), HIS (A:32), VAL (A:30), CYS (A:37), GLN (A:35), and LYS (A:54). The Pi-Pi T-Shaped interaction with HIS (A:32) suggests that the aromatic structure of curcumin may form a planar interaction with the Histidine side chain, stabilizing the binding. Pi-Sulfur interactions with CYS (A:37), as well as Amide-Pi Stacked and Pi-Alkyl interactions with LYS (A:54), indicate that the ligand is engaging in both hydrophobic and electrostatic interactions, enhancing the overall binding stability. The variety of binding interactions, including carbon-hydrogen bonds and alkyl interactions, suggests that curcumin has a strong binding profile that could contribute to effective inhibition of the protease. Curcuminol also forms a wide array of interactions, including Pi-Alkyl, conventional hydrogen bonds, Pi-Sulfur, and alkyl interactions. The key binding residues include GLN (A:60), LYS (A:54), ILE (A:52), TYR (A:50), CYS (A:37), and LEU (A:53). Pi-Alkyl interactions with LYS (A:54) and VAL (A:30) suggest that hydrophobic interactions between the aromatic rings of the ligand and these residues are critical for stabilizing the complex. The Pi-Sulfur interaction with PHE (A:64) indicates that sulfur-containing groups may participate in aromatic stacking interactions, further stabilizing the ligand\u0026rsquo;s binding within the active site. Hydrogen bonds at multiple sites (e.g., GLN (A:60) and LYS (A:54)) likely contribute to enhancing the ligand's affinity for the protease. Demethoxycurcumin primarily forms Pi-Alkyl, hydrogen bonds, and conventional hydrogen bonds with PRO (A:26) and ARG (A:27). The Pi-Alkyl interactions at ARG (A:27) indicate the potential for strong hydrophobic interactions, which may help anchor the ligand in the active site. The presence of conventional hydrogen bonds with PRO (A:26) suggests a stable binding orientation, which could be beneficial for maintaining the interaction with the protease. Isorhamnetin exhibits a mix of Pi-Alkyl, hydrogen bonds, alkyl interactions, and unfavorable acceptor-acceptor interactions. Significant binding residues include ILE (A:52), THR (A:47), ARG (A:27), SER (A:42), PHE (A:43), LEU (A:53), and LYS (A:54). Pi-Alkyl interactions with ARG (A:27) and ILE (A:52) suggest that the ligand\u0026rsquo;s aromatic rings are engaging in hydrophobic interactions with these key residues, stabilizing the complex. The unfavorable acceptor-acceptor interactions observed at SER (A:42) and LEU (A:53) may indicate some steric hindrance or a less favorable binding conformation, which could reduce the overall binding efficiency and effectiveness as an inhibitor. Ribavirin forms several key interactions, including Pi-Alkyl, conventional hydrogen bonds, and carbon-hydrogen bonds with PRO (A:26), LEU (A:25), ASP (A:41), ARG (A:27), THR (A:47), and ALA (A:55). The Pi-Alkyl interaction with ARG (A:27) and ALA (A:55) suggests that the ligand is interacting with hydrophobic regions in the enzyme\u0026rsquo;s active site, which could contribute to its binding stability. Conventional hydrogen bonds with ASP (A:41) and THR (A:47) provide additional stabilizing interactions, enhancing the ligand\u0026rsquo;s binding affinity. Curcumin, bisdemethoxycurcumin, and curcuminol exhibit a diverse set of interactions with the protease, including Pi-Alkyl, Pi-Pi T-Shaped, Pi-Sulfur, and hydrogen bonds, which suggest that these ligands are well-positioned to engage the enzyme in a stable and specific manner. The presence of Pi-Sulfur interactions with CYS (A:37) in curcumin and curcuminol highlights the potential for unique interaction profiles that could improve binding affinity. Demethoxycurcumin and ribavirin show more limited interaction profiles, which may influence their binding potency and specificity. However, ribavirin still shows some significant binding interactions, which could be optimized for better protease inhibition. Hydrogen bonding is a crucial interaction for ligand binding and specificity. Ligands such as curcumin and curcuminol form multiple hydrogen bonds with residues like GLN (A:35), GLN (A:60), and LYS (A:54), which contribute to their high binding affinity. Isorhamnetin, while forming several hydrogen bonds, also experiences unfavorable acceptor-acceptor interactions that may reduce its overall binding stability, which could limit its effectiveness. Isorhamnetin and ribavirin exhibit some unfavorable acceptor-acceptor interactions, which may hinder optimal binding to the protease and reduce their overall effectiveness as inhibitors. Isorhamnetin, in particular, may need structural modifications to overcome these interactions and enhance binding efficiency.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec16\" class=\"Section2\"\u003e\u003ch2\u003e3.7 Ligand binding interactions with the PVY coat protein\u003c/h2\u003e\u003cp\u003eThe ligand binding interactions with the PVY CP (pfam00767) are summarized in Table\u0026nbsp;(7) and Fig.\u0026nbsp;(6), providing insights into the types of interactions formed between the ligands and the key amino acid residues in the protein\u0026rsquo;s structure. These interactions, including Pi-Cation, hydrogen bonds, and carbon-hydrogen bonds, play a crucial role in the persistence and affinity of ligand binding, which is vital for the development of effective inhibitors. Curcumin forms various interactions, including Pi-Cation, conventional hydrogen bonds, carbon-hydrogen bonds, and unfavorable donor-donor interactions. The Pi-Cation interaction with ARG (A:55) suggests a strong aromatic interaction, which stabilizes binding in the hydrophobic pocket. Hydrogen bonds are formed with GLN (A:140), GLY (A:61), and LYS (A:60), enhancing the ligand\u0026rsquo;s affinity for the protein. Unfavorable donor-donor interactions with GLN (A:140) suggest some steric hindrance, potentially reducing binding efficiency. The Pi-Alkyl interaction with HIS (A:162) further stabilizes the ligand-protein complex. Isorhamnetin forms multiple hydrogen bonds with ARG (A:55) and ASP (A:91), suggesting that these interactions are important for maintaining the ligand\u0026rsquo;s position within the binding site, thereby enhancing its binding affinity. However, the ligand forms fewer interactions compared to curcumin, indicating a potentially less stable binding. Ribavirin forms hydrogen bonds with ASN (A:82), THR (A:86), TRP (A:118), and GLY (A:130). It also exhibits Pi-lone pair interactions with THR (A:86), suggesting non-covalent interactions that enhance binding specificity. Carbon-hydrogen bonds with GLY (A:130) further contribute to binding stability. Overall, ribavirin's interaction profile suggests stable binding, though potentially weaker or less specific compared to other ligands.\u003c/p\u003e\u003c/div\u003e"},{"header":"4 Discussion","content":"\u003cp\u003eThe analysis of the physicochemical properties of the ligands offers important insights into their potential bioactivity, pharmacokinetics, and overall drug-likeness. Molecular weight is a critical factor influencing absorption, distribution, metabolism, and excretion (ADME) characteristics. Generally, smaller molecules exhibit improved membrane permeability and absorption, whereas larger molecules often face challenges related to poor solubility and reduced bioavailability. Among the ligands evaluated, Curcuminol, with a molecular weight of 566.51 g/mol, is the heaviest, which may negatively impact its absorption and oral bioavailability. Conversely, compounds such as Caffeic acid and Sinapic acid, which possess lower molecular weights, are likely to demonstrate better absorption profiles. Most ligands fall within the typical molecular weight range for drug-like compounds (200\u0026ndash;500 g/mol), with Curcuminol as the notable exception, suggesting potential limitations for its oral administration [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. These findings align with established knowledge that smaller molecules generally achieve superior membrane permeability and absorption, while larger compounds may be hindered by poor solubility and permeability issues [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. The number of rotatable bonds influences the flexibility of a molecule, which can have both positive and negative implications for binding to biological targets. A higher number of rotatable bonds can increase the conformational diversity of a molecule, potentially improving its ability to bind to a range of targets. However, excessive flexibility could lead to instability and reduced specificity. Curcuminol, with 13 rotatable bonds, is the most flexible molecule in the set, which could increase its potential for binding to various targets but might also compromise its stability. On the other hand, compounds like Curdione (1 RB) and Caffeic acid (2 RB) are more rigid, which may offer better specificity for well-defined targets, although it could limit their binding diversity [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. The hydrogen bonding capacity of a compound influences its solubility and interaction with biomolecules. Compounds with a high number of HBA and donors (HBD) can exhibit strong interactions with biological targets, but excessive hydrogen bonding may reduce membrane permeability [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. Curcuminol and isorhamnetin, with the highest number of HBA (12 and 7, respectively), may have strong interactions with the polar regions of biological targets. However, such compounds may also face challenges in terms of membrane permeability. Curdione, with only 2 HBA and no HBD, is less likely to engage in hydrogen bonding, potentially reducing its bioactivity but increasing its specificity. Ribavirin, with a balanced hydrogen bonding profile, could be seen as an optimized structure for maintaining bioactivity while potentially having favorable ADME properties [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe physicochemical and ADMET profiles of the tested ligands reveal significant insights into their potential as antiviral agents against the PVY\u003csup\u003eN\u003c/sup\u003e-Egypt strain. Curcuminol, despite its high molecular weight and flexibility, violates Lipinski\u0026rsquo;s rule and shows low gastrointestinal absorption, which may limit its oral bioavailability and clinical application, consistent with previous observations that large, flexible molecules often face bioavailability challenges [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. In contrast, ligands like curcumin, bisdemethoxycurcumin, and isorhamnetin exhibit favorable drug-like properties with high GI absorption and compliance with Lipinski\u0026rsquo;s rule, highlighting their potential as orally active candidates [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. The toxicity profiles further refine candidate selection, as compounds such as curdione and curcuminol show potential toxicity, warranting caution in further development [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eVirtual screening results demonstrated strong binding affinities of curcuminoids and flavonoids to key viral proteins, with isorhamnetin and bisdemethoxycurcumin showing particularly promising interactions with the P1 protease and helper component proteinase, suggesting their role as potent inhibitors in viral replication and transmission processes [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]. The control drug ribavirin, despite moderate binding affinity, confirms the validity of the docking approach and underscores the improved efficacy of these natural ligands in targeting PVY proteins [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]. Detailed interaction analyses reveal that hydrogen bonding, Pi-Alkyl, and salt bridge formations are critical in ligand stabilization within the active sites, aligning with prior studies that emphasize the importance of multi-modal interactions for effective protease inhibition [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eMoreover, the inability of most ligands to permeate the blood-brain barrier aligns with the peripheral targeting profile required for plant viral infections, reducing the risk of central nervous system side effects [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. However, bisdemethoxycurcumin and curdione\u0026rsquo;s BBB permeability may open avenues for broader antiviral applications but require further toxicity assessment. Collectively, these findings suggest that the curcuminoids and flavonoids under study merit further in vitro and in vivo validation as potential antiviral agents, especially given their multifaceted interaction profiles and favorable ADMET characteristics, supporting the growing body of evidence on natural products as valuable scaffolds in antiviral drug discovery [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e, \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eGI absorption is a critical determinant of oral bioavailability, as compounds with high GI absorption are generally absorbed more efficiently from the gastrointestinal tract. In this dataset, most compounds are predicted to have high GI absorption, which is a favorable characteristic for potential drug development. However, curcuminol and ribavirin, with predicted low GI absorption, could face challenges related to oral bioavailability. These compounds might experience poor intestinal permeability or high first-pass metabolism, which can limit their therapeutic effectiveness [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe ability of a compound to cross the blood-brain barrier (BBB) is critical for drugs targeting the CNS. In this dataset, bisdemethoxycurcumin and Curdione are predicted to be BBB permeant, suggesting their potential for treating CNS-related diseases. On the other hand, most other ligands, such as Caffeic acid, curcumin, and demethoxycurcumin, are not predicted to cross the BBB, suggesting they may be more effective for treating peripheral diseases [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eCytochrome P450 (CYP) enzymes are essential for the metabolism of numerous drugs, and their inhibition can result in potentially harmful drug-drug interactions. Bisdemethoxycurcumin and demethoxycurcumin are predicted to inhibit multiple CYP isoforms, raising concerns about significant interactions when co-administered with other therapeutics. Likewise, curcumin, isorhamnetin, and ribavirin inhibit CYP3A4, a key enzyme involved in the metabolism of a wide variety of drugs [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. Therefore, the potential for CYP enzyme inhibition must be carefully evaluated during drug development, especially when these compounds are intended for use alongside other medications that depend on CYP-mediated metabolism [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eLipinski\u0026rsquo;s \"Rule of Five\" provides a widely accepted framework for assessing the drug-likeness of compounds, with adherence suggesting favorable oral bioavailability. In this analysis, most compounds, with the exception of curcuminol, conform to Lipinski\u0026rsquo;s criteria, indicating promising drug-like properties and a higher likelihood of oral absorption. Curcuminol, however, due to its large molecular weight and elevated hydrogen bonding capacity, violates Lipinski\u0026rsquo;s rule, which may pose challenges related to solubility and oral bioavailability [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eToxicity is a critical consideration in drug development, and compounds that are classified as toxic may pose risks for patient safety. In this dataset, curcuminol and Curdione are classified as toxic, suggesting that despite their promising ADMET properties, they may exhibit undesirable side effects that limit their therapeutic use. Conversely, compounds such as ribavirin, which are classified as non-toxic, may present fewer safety concerns, making them more suitable for further development. Therefore, toxicity must be considered alongside efficacy and ADMET properties to ensure the safe development of these compounds as potential therapeutics. In a summary, the ligands in this virtual screening dataset demonstrate varied ADMET properties, which can be linked to their pharmacological potential [\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eBisdemethoxycurcumin, Curdione, and demethoxycurcumin show high GI absorption and favorable pharmacokinetic properties, though some of them are predicted to inhibit multiple CYP enzymes, raising concerns about drug-drug interactions. Curcumin, isorhamnetin, and ribavirin also show good absorption and drug-like properties but may exhibit interactions with CYP3A4. On the other hand, curcuminol exhibits poor GI absorption, does not comply with Lipinski's rule, and is classified as toxic, indicating that it may require substantial modifications to improve its drug-like properties and safety profile. Caffeic acid and Sinapic acid have high GI absorption and do not inhibit CYP enzymes, making them interesting candidates for further studies targeting peripheral diseases. The strong binding of Isorhamnetin to the P1 protease, with a binding affinity of -7.1 kcal/mol, highlights its potential as a lead compound for antiviral drug design targeting this key enzyme in the PVY\u003csup\u003eN\u003c/sup\u003e-Egypt strain. Curcuminoids like Bisdemethoxycurcumin and Curcumin also demonstrate promising binding affinities, which is consistent with their previously reported antiviral properties [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Curcuminoids have shown broad-spectrum activity against various viruses, including plant viruses, suggesting that they could be used to inhibit P1 protease activity in PVY [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eBisdemethoxycurcumin, Demethoxycurcumin, and Isorhamnetin show the most favorable binding to HCPro, with binding affinities of -6.4 kcal/mol. This is significant because HCPro plays an essential role in viral transmission and replication. The observed high binding affinities of curcuminoids and flavonoids like Isorhamnetin align with studies that report their broad-spectrum antiviral properties, particularly against plant viruses [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e, \u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]. This suggests that these compounds may effectively inhibit HCPro activity, thereby reducing PVY replication and transmission. Curcumin and Isorhamnetin demonstrate the strongest binding affinities for the PVY\u003csup\u003eN\u003c/sup\u003e-Egypt coat protein at -7.4 kcal/mol, which could potentially interfere with viral capsid formation and RNA encapsidation, crucial steps for the virus's stability and transmission. The observed results are consistent with previous findings that curcuminoids can disrupt viral capsid formation [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e, \u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e], and Isorhamnetin, a flavonoid, has shown promising antiviral activity in several studies [\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e]. This suggests that both compounds could play a significant role in disrupting the viral lifecycle by targeting the coat protein.\u003c/p\u003e\u003cp\u003eThe RMSD (Root Mean Square Deviation) values of 0.0 observed across all ligand\u0026ndash;protein complexes may initially suggest high accuracy in the docking predictions, indicating that the predicted binding poses are closely aligned with the reference conformations. However, such uniformly low RMSD values can also reflect methodological limitations, particularly when rigid docking protocols are employed. In this study, ligands were docked back into their native conformations without allowing for conformational flexibility or sampling of alternative binding modes. While this approach confirms pose reproducibility, it does not fully account for the dynamic nature of ligand\u0026ndash;protein interactions in realistic biological environments [\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e, \u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e]. We acknowledge this as a limitation of the current methodology and recommend that future studies incorporate flexible docking protocols or molecular dynamics simulations to enhance the predictive accuracy [\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e]. Accordingly, we have conducted a limited re-evaluation using flexible docking in this revision to support the reliability of our findings.\u003c/p\u003e\u003cp\u003eOverall, the ligand binding affinities obtained in this study identify promising candidates for the development of antiviral agents against the PVYN-Egypt strain. Curcumin, Isorhamnetin, and Bisdemethoxycurcumin demonstrated strong binding across all three target proteins, underscoring their potential as broad-spectrum antiviral compounds. These findings are consistent with previous studies reporting the antiviral efficacy of curcumin derivatives and flavonoids, which have been shown to inhibit viral replication and disrupt key protein functions [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e]. Additionally, Ribavirin, employed here as a standard antiviral control, exhibited comparatively strong binding affinities, reaffirming its established antiviral activity [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. The docking results emphasize that curcumin derivatives and flavonoids\u0026mdash;particularly Bisdemethoxycurcumin, Curcumin, and Isorhamnetin\u0026mdash;possess strong affinity for critical proteins of the PVYN-Egypt strain. This aligns with the well-documented antiviral properties of curcuminoids, which are known to suppress viral proliferation by targeting essential viral enzymes and protein functions [\u003cspan additionalcitationids=\"CR46\" citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe high binding affinity of Isorhamnetin, a flavonoid, further supports the potential of flavonoids in antiviral drug discovery [\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e, \u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e]. Additionally, Ribavirin, a well-known antiviral drug, exhibited docking scores in the moderate range across all three proteins. While its binding affinity was lower than that of curcumin derivatives and Isorhamnetin, Ribavirin's established antiviral activity [\u003cspan additionalcitationids=\"CR51 CR52\" citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e53\u003c/span\u003e], makes it a valuable control in this study. Bisdemethoxycurcumin, curcumin, and isorhamnetin show strong binding interactions with PVY P1 protease, particularly through a combination of Pi-Alkyl, Pi-Anion, hydrogen bonds, and Pi-Cation interactions. These ligands seem to have a well-established binding profile with significant contributions from both hydrophobic and polar interactions, which may contribute to their high binding affinity [\u003cspan additionalcitationids=\"CR55\" citationid=\"CR53\" class=\"CitationRef\"\u003e54\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e56\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe salt bridge formation observed with GLU (J:2974) in isorhamnetin could indicate a more stable binding compared to other ligands, potentially making isorhamnetin a better candidate for inhibition [\u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e57\u003c/span\u003e]. Hydrogen bonding is a critical component of ligand-receptor interactions and significantly contributes to binding affinity and specificity. The ligands bisdemethoxycurcumin, curcumin, and isorhamnetin form multiple hydrogen bonds with residues like GLN, SER, and ARG, which help stabilize the ligand-receptor complex [\u003cspan additionalcitationids=\"CR49\" citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e]. Ribavirin also forms hydrogen bonds, but the presence of unfavorable acceptor-acceptor interactions suggests that its binding affinity might be weaker or less stable compared to the other ligands. The unfavorable acceptor-acceptor interactions in ribavirin (with MET (M:2895) and ASN (F:2971) may reduce its binding efficiency and increase the likelihood of off-target effects or weaker inhibition. This suggests that ribavirin may require structural modifications to improve its binding profile and reduce unfavorable interactions [\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e61\u003c/span\u003e, \u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e62\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eBased on the detailed binding analysis, bisdemethoxycurcumin, curcumin, and isorhamnetin are strong candidates for further drug development targeting PVY P1 protease, given their favorable interaction profiles and strong binding affinities. These ligands could be optimized through structural modifications to improve potency, selectivity, and minimize toxicity [\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e63\u003c/span\u003e]. Ribavirin, while having some beneficial interactions, may need structural optimization to overcome the unfavorable interactions and enhance its overall binding stability. Based on the diverse and stable interactions with key amino acids in the protease, curcumin, bisdemethoxycurcumin, and curcuminol appear to be strong candidates for further optimization and development as potent protease inhibitors. These ligands display a wide range of favorable interactions, indicating that they could effectively bind to and inhibit the PVY helper component proteinase.\u003c/p\u003e\u003cp\u003eThe variety of interactions, including Pi-Alkyl, Pi-Sulfur, Pi-Pi T-Shaped, and hydrogen bonding, suggests that these compounds are engaging in both hydrophobic and electrostatic interactions that contribute to their high binding affinity [\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e64\u003c/span\u003e, \u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e65\u003c/span\u003e]. In particular, the Pi-Sulfur interactions with CYS (A:37) observed in curcumin and curcuminol highlight the potential for unique interaction profiles, which may improve the binding affinity and specificity for the protease. These interactions may provide these ligands with an advantage in terms of potency and selectivity for the target enzyme [\u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e66\u003c/span\u003e]. Moreover, the diversity of bonding types seen in bisdemethoxycurcumin and curcuminol-such as Pi-Alkyl, Pi-Pi T-Shaped, and hydrogen bonds-suggests that these compounds could engage the protease in a stable, multifaceted manner, likely enhancing their inhibitory potential [\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e67\u003c/span\u003e]. While demethoxycurcumin and ribavirin show more limited interaction profiles, they still exhibit significant binding interactions, suggesting that their structures could be further optimized for better protease inhibition. The more limited interaction profiles may indicate that these compounds are less stable in the active site compared to curcumin derivatives, potentially reducing their potency as inhibitors. Structural modifications could improve these interactions and enhance the binding efficiency [\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e56\u003c/span\u003e, \u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e68\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eIsorhamnetin, despite forming several hydrogen bonds, exhibits unfavorable acceptor-acceptor interactions that may reduce its overall binding stability, thereby limiting its effectiveness as a protease inhibitor. These unfavorable interactions, especially with residues such as SER (A:42) and LEU (A:53), may result in steric hindrance or decreased affinity. Therefore, isorhamnetin could benefit from structural modifications aimed at overcoming these unfavorable interactions to enhance binding efficiency and improve its inhibitory potency [\u003cspan citationid=\"CR68\" class=\"CitationRef\"\u003e69\u003c/span\u003e, \u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e70\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eCurcumin, bisdemethoxycurcumin, and curcuminol generally emerge as promising candidates for further development as protease inhibitors targeting the PVY helper component proteinase. Although isorhamnetin and ribavirin exhibit some potential, they may require structural optimization to mitigate unfavorable interactions and enhance their overall inhibitory efficacy [\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e, \u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e70\u003c/span\u003e]. Analysis of the binding interactions with the PVY coat protein highlights curcumin as the strongest candidate for development as a protease inhibitor against this target. The compound\u0026rsquo;s robust and stable binding affinity is likely driven by a diverse array of interactions, including Pi-Cation, Pi-Alkyl, and hydrogen bonds [\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e67\u003c/span\u003e, \u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e71\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eNotably, curcumin forms Pi-Cation interactions with ARG (A:55) and Pi-Alkyl interactions with HIS (A:162), indicating engagement through both hydrophobic and aromatic contacts, which contribute to a stable binding conformation. Furthermore, hydrogen bonds with residues such as GLN (A:140), GLY (A:61), and LYS (A:60) further reinforce the stability of the curcumin-protein complex, enhancing its affinity for the PVY coat protein [\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e, \u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e72\u003c/span\u003e]. However, an unfavorable donor-donor interaction with GLN (A:140) suggests possible steric clashes or electrostatic repulsion that could detract from curcumin\u0026rsquo;s binding efficiency at this site. Addressing this issue in future ligand optimization\u0026mdash;potentially through structural modifications to reduce steric hindrance or electrostatic conflict\u0026mdash;may improve binding potency [\u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e73\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eIsorhamnetin, while promising as a ligand for the PVY coat protein, forms fewer interaction types compared to curcumin. It mainly establishes hydrogen bonds with key residues such as ARG (A:55) and ASP (A:91), suggesting effective binding, though possibly with lower affinity due to the more limited interaction profile [\u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e74\u003c/span\u003e, \u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e75\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eStructural modifications aimed at enhancing the interaction profile\u0026mdash;such as increasing hydrophobic contacts or introducing additional binding moieties\u0026mdash;could improve the inhibitory potency and specificity of these compounds. Ribavirin forms stable hydrogen bonds with residues including ASN (A:82), THR (A:86), TRP (A:118), and GLY (A:130). Additionally, a Pi-lone pair interaction with THR (A:86) may contribute to binding specificity; however, ribavirin\u0026rsquo;s overall interaction profile is simpler compared to curcumin\u0026rsquo;s, which limits its binding affinity. Consequently, ribavirin may benefit from optimization to enhance its Pi-lone pair interactions and overall binding conformation [\u003cspan citationid=\"CR75\" class=\"CitationRef\"\u003e76\u003c/span\u003e]. Among the compounds studied, curcumin stands out as the most promising candidate for further development, owing to its diverse and stabilizing interactions, particularly the Pi-Cation and Pi-Alkyl interactions [\u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e77\u003c/span\u003e, \u003cspan citationid=\"CR77\" class=\"CitationRef\"\u003e78\u003c/span\u003e]. Isorhamnetin also shows potential for optimization, displaying favorable hydrogen bonding; yet, its affinity may be comparatively lower due to the narrower range of interaction types. Ribavirin, while forming stable interactions, is likely to require structural refinement to improve both its binding affinity and specificity for the PVY coat protein.\u003c/p\u003e\u003cp\u003e\u003cb\u003eLimitations\u003c/b\u003e\u003c/p\u003e\u003cp\u003eWhile the docking results indicate promising binding interactions with RMSD values close to zero, it is important to recognize the inherent limitations of molecular docking simulations. Such ideal RMSD values may reflect methodological constraints, including limited sampling of ligand-protein conformations and reliance on static protein structures. Moreover, docking predictions are inherently computational and provide only a preliminary understanding of molecular interactions. Therefore, these findings should be interpreted as hypotheses that require subsequent experimental validation through in vitro and in vivo studies. Additionally, the complex dynamics of biological systems and potential off-target effects are not fully captured in silico, underscoring the need for cautious interpretation and further comprehensive investigations.\u003c/p\u003e\u003cp\u003e\u003cb\u003eFuture Directions\u003c/b\u003e\u003c/p\u003e\u003cp\u003eBuilding on the promising in silico findings of this study, future research should focus on experimental validation through in vitro assays to confirm the antiviral activity of the identified turmeric-derived compounds against PVY. Subsequently, in vivo studies will be essential to evaluate their efficacy and safety in plant models. Additionally, structural modifications of these bioactive molecules could be explored to enhance their binding affinity, bioavailability, and specificity. Investigating potential synergistic effects through combination therapies with existing antiviral agents may also provide more effective control strategies. Ultimately, integrating computational predictions with empirical data will facilitate the development of novel, targeted antiviral treatments for crop protection.\u003c/p\u003e"},{"header":"5 Conclusion","content":"\u003cp\u003eThese findings underscore the potential of curcumin derivatives and flavonoids as lead compounds in the development of antiviral agents against the PVY\u003csup\u003eN\u003c/sup\u003e-Egypt strain. Nonetheless, further in vitro and in vivo studies are necessary to validate their efficacy and safety. This study highlights turmeric-derived compounds, particularly curcuminoids, as promising antiviral candidates targeting key PVY proteins. Molecular docking analysis revealed that isorhamnetin exhibits strong affinity for the P1 protease, while curcumin and bisdemethoxycurcumin interact effectively with HCPro and CP, suggesting their potential to disrupt viral replication. ADMET profiling indicated favorable bioavailability and gastrointestinal absorption for most curcumin derivatives. However, curcuminol and ribavirin showed potential toxicity concerns. In summary, natural compounds such as curcuminoids and flavonoids-especially isorhamnetin-demonstrate significant promise as antiviral agents against PVY\u003csup\u003eN\u003c/sup\u003e-Egypt. These results support further experimental research for both agricultural protection and pharmaceutical development.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003e2D Two D structure\u003c/p\u003e\n\u003cp\u003e3D Three D structure\u003c/p\u003e\n\u003cp\u003eADMET Absorption, Distribution, Metabolism, Excretion, and Toxicity\u003c/p\u003e\n\u003cp\u003eBBB Blood-brain barrier\u003c/p\u003e\n\u003cp\u003eCNS Central nervous system\u003c/p\u003e\n\u003cp\u003eCP Coat protein\u003c/p\u003e\n\u003cpre\u003eCYP\u003cspan dir=\"RTL\"\u003e \u003c/span\u003eCytochrome P450\u003c/pre\u003e\n\u003cp\u003eg/mol Gram/mole\u003c/p\u003e\n\u003cp\u003eGI Gastrointestinal\u003c/p\u003e\n\u003cp\u003eHBA Hydrogen bond acceptors\u003c/p\u003e\n\u003cp\u003eHBD Hydrogen bond donors\u003c/p\u003e\n\u003cp\u003eHCPro Helper component proteinase\u003c/p\u003e\n\u003cp\u003eHIV Human Immunodeficiency Virus\u003c/p\u003e\n\u003cp\u003elb Lower bound\u003c/p\u003e\n\u003cp\u003eMW Molecular weight\u003c/p\u003e\n\u003cp\u003eNCBI National center for biotechnology information\u003c/p\u003e\n\u003cp\u003eNT Non-Toxic\u003c/p\u003e\n\u003cp\u003ePDB Protein Data Bank\u003c/p\u003e\n\u003cp\u003ePVX Potato virus X\u003c/p\u003e\n\u003cp\u003ePVY Potato Virus Y\u003c/p\u003e\n\u003cp\u003eRB Rotatable bonds\u003c/p\u003e\n\u003cp\u003eRMSD Root mean square deviation\u003c/p\u003e\n\u003cp\u003eRNA Ribonucleic acid\u003c/p\u003e\n\u003cp\u003eT Toxic\u003c/p\u003e\n\u003cp\u003eTMV Tobacco mosaic virus\u003c/p\u003e\n\u003cp\u003eub Upper bound\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eEthical approval was not applicable for this study, as it involved only plant and microbial samples, which do not require review by a human or animal ethics committee\u003c/p\u003e\n\u003ch4\u003e\u003cstrong\u003eConsent for Publication\u003c/strong\u003e\u003c/h4\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and material\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that no funds, grants, or other support were received during the preparation of this manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eJones RA (2006) Control of plant virus diseases. Advances in Virus Research 67:205-244.\u003cspan dir=\"RTL\"\u003e\u0026rlm; \u003c/span\u003ehttps://doi.org/10.1016/S0065-3527(06)67006-1Get rights and content\u003c/li\u003e\n\u003cli\u003eQuenouille J, Vassilakos N, Moury B (2013) Potato virus Y: A major crop pathogen that has provided major insights into the evolution of viral pathogenicity. Molecular plant pathology 14(5):439-452.\u003cstrong\u003e\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003e\u003c/strong\u003ehttps://doi.org/10.1111/mpp.12024\u003c/li\u003e\n\u003cli\u003eNasr-Eldin MA, Othman BA, Megahed AA, et al (2018) Physiological, cytological and molecular analysis of PVY\u003csup\u003eNTN\u003c/sup\u003e-infected potato cultivars. Egyptian Journal of Experimental Biology (Botany) 14(1):171-185. https://www.ejmanager.com/mnstemps/15/151519330872.pdf?t=1554029194)\u003c/li\u003e\n\u003cli\u003eValkonen JP (2007) Viruses: economical losses and biotechnological potential. In Potato biology and biotechnology (pp. 619-641). Elsevier Science BV.\u003cstrong\u003e\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003e\u003c/strong\u003ehttps://doi.org/10.1016/B978-044451018-1/50070-1\u003c/li\u003e\n\u003cli\u003eNasr-Eldin M, Messiha N, Othman B, et al (2019) Induction of potato systemic resistance\u003cspan dir=\"RTL\"\u003e \u003c/span\u003eagainst the \u003cem\u003ePotato virus Y\u003c/em\u003e (PVY\u003csup\u003eNTN\u003c/sup\u003e), using\u003cspan dir=\"RTL\"\u003e \u003c/span\u003ecrude filtrates of \u003cem\u003eStreptomyces\u003c/em\u003e spp. under\u003cspan dir=\"RTL\"\u003e \u003c/span\u003egreenhouse conditions. Egyptian Journal of Biological Pest Control 29(62):1-11. https://doi.org/10.1186/s41938-019-0165-1\u003c/li\u003e\n\u003cli\u003eAbd El-Aziz MH (2020) The importance of \u003cem\u003ePotato virus Y\u003c/em\u003e Potyvirus. Journal of Plant Science and Phytopathology 4:009-015.\u003cstrong\u003e\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003e\u003c/strong\u003edx.doi.org/10.29328/journal.jpsp.1001044\u003c/li\u003e\n\u003cli\u003eAdams MJ, Antoniw JF, Fauquet CM (2005) Molecular criteria for genus and species discrimination within the family \u003cem\u003ePotyviridae\u003c/em\u003e. Archives of Virology 150(3):459-479. https://doi.org/10.1007/s00705-004-0440-6\u003c/li\u003e\n\u003cli\u003eBekhit AED, Bekhit AA (2014) Natural antiviral compounds. Studies in Natural Products Chemistry 42: 195-228. https://doi.org/10.1016/B978-0-444-63281-4.00007-0\u003c/li\u003e\n\u003cli\u003eAnand P, Kunnumakkara AB, Newman RA, et al (2008) Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics 4(6):807-818. https://doi.org/10.1021/mp700113r\u003c/li\u003e\n\u003cli\u003eJennings MR, Parks RJ (2020) Curcumin as an antiviral agent. Viruses 12(11):1242.\u003cspan dir=\"RTL\"\u003e\u0026rlm; \u003c/span\u003ehttps://doi.org/10.3390/v12111242\u003c/li\u003e\n\u003cli\u003eArdebili A, Pouriayevali MH, Aleshikh S, et al (2021) Antiviral therapeutic potential of curcumin: An update. Molecules 26(22):6994.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.3390/molecules26226994\u003c/li\u003e\n\u003cli\u003ePagadala NS, Syed K, Tuszynski J (2017) Software for molecular docking: A review. Biophysical Reviews 9(2):91-102. https://doi.org/10.1007/s12551-016-0247-1\u003c/li\u003e\n\u003cli\u003eFerreira LG, Dos Santos RN, Oliva, G, et al (2015) Molecular docking and structure-based drug design strategies. Molecules 20(7):13384-13421.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttp://dx.doi.org/10.3390/molecules200713384\u003c/li\u003e\n\u003cli\u003eMorris GM, Lim-Wilby M (2008) Molecular docking. Molecular Modeling of Proteins 365-382.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1007/978-1-59745-177-2_19\u003c/li\u003e\n\u003cli\u003eAseel DG, Rabie M, El-Far A, et al (2024) Antiviral properties and molecular docking studies of eco-friendly biosynthesized copper oxide nanoparticles against alfalfa mosaic virus. BMC Plant Biology 24(1):1089. \u003cstrong\u003e\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003e\u003c/strong\u003ehttps://doi.org/10.1186/s12870-024-05802-1\u003c/li\u003e\n\u003cli\u003eBehl T, Rocchetti G, Chadha S, et al (2021) Phytochemicals from plant foods as potential source of antiviral agents: An overview. Pharmaceuticals 14(4):381.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.3390/ph14040381\u003c/li\u003e\n\u003cli\u003eSiddiqi MH, Siddiqi MZ, Kim SP (2019) Advances in molecular docking for antiviral drug discovery. Current Bioinformatics 14(3):240-254. https://doi.org/10.3390/md18110545\u003c/li\u003e\n\u003cli\u003eDaina A, Michielin O, Zoete V (2017) SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports 7(1):1-13.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1038/srep42717\u003c/li\u003e\n\u003cli\u003eHonorio MK, Moda LT, Andricopulo AD (2013) Pharmacokinetic properties and in silico ADME modeling in drug discovery. Medicinal Chemistry 9(2):163-176.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttp://dx.doi.org/10.2174/1573406411309020002\u003c/li\u003e\n\u003cli\u003eVeber DF, Johnson SR, Cheng HY, et al (2002) Molecular properties that influence the oral bioavailability of drug candidates. Journal of medicinal chemistry 45(12):2615-2623. https://doi.org/10.1021/jm020017n\u003c/li\u003e\n\u003cli\u003eMaltarollo VG, Gertrudes JC, Oliveira PR, et al (2015) Applying machine learning techniques for ADME-Tox prediction: a review. Expert Opinion on Drug Metabolism and Toxicology 11(2):259-271. https://doi.org/10.1517/17425255.2015.980814\u003c/li\u003e\n\u003cli\u003eAlqahtani S (2017) In silico ADME-Tox modeling: progress and prospects. Expert opinion on drug metabolism and toxicology 13(11):1147-1158.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1080/17425255.2017.1389897\u003c/li\u003e\n\u003cli\u003eGraci JD, Cameron CE (2006) Mechanisms of action of ribavirin against distinct viruses. Reviews in Medical Virology 16(1):37-48.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1002/rmv.483\u003c/li\u003e\n\u003cli\u003eLipinski CA, Lombardo F, Dominy BW, et al (2012) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 64:4-17. https://doi.org/10.1016/j.addr.2012.09.019\u003c/li\u003e\n\u003cli\u003eGhose AK, Viswanadhan VN, Wendoloski JJ (1999) A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. Journal of Combinatorial Chemistry 1(1):55-68. https://doi.org/10.1021/cc9800071\u003c/li\u003e\n\u003cli\u003eEkins S, Mestres J, Testa B (2007) In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. British Journal of Pharmacology 152(1):9-20. https://doi.org/10.1038/sj.bjp.0707305\u003c/li\u003e\n\u003cli\u003eDe Clercq E (2006) Antiviral agents active against influenza A viruses. Nature Reviews Drug Discovery 5(12):1015-1025. https://doi.org/10.1038/nrd2175\u003c/li\u003e\n\u003cli\u003eMorris GM, Huey R, Lindstrom W, et al (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry 30(16):2785-2791. https://doi.org/10.1002/jcc.21256\u003c/li\u003e\n\u003cli\u003ePardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2(1):3-14. https://doi.org/10.1602/neurorx.2.1.3\u003c/li\u003e\n\u003cli\u003eNewman DJ, Cragg GM (2016) Natural products as sources of new drugs from 1981 to 2014. Journal of Natural Products 79(3):629-661. https://doi.org/10.1021/acs.jnatprod.5b01055\u003c/li\u003e\n\u003cli\u003eHarvey AL, Edrada-Ebel R, Quinn RJ (2015) The re-emergence of natural products for drug discovery in the genomics era. Nature Reviews Drug Discovery 14(2):111-129. https://doi.org/10.1038/nrd4510\u003c/li\u003e\n\u003cli\u003eVasconcelos T, Sarmento B, Costa P (2007) Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discovery Today 12(23-24):1068-1075.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1016/j.drudis.2007.09.005\u003c/li\u003e\n\u003cli\u003ePardridge WM (2007) Blood\u0026ndash;brain barrier delivery. Drug discovery today 12(1-2):54-61.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1016/j.drudis.2006.10.013\u003c/li\u003e\n\u003cli\u003eChoong CL, Islahudin F, Makmor-Bakry M, et al (2024). Effect of CYP3A5* 3, ABCC2 C-24T, and ABCC2 C3972T genetic polymorphisms on direct cost of kidney transplant recipients. Cureus 16(9): e69221. doi: 10.7759/cureus.69221\u003c/li\u003e\n\u003cli\u003eZhang Y, Wang Z, Wang Y, et al (2024). CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms. PeerJ 12:p.e18636. https://peerj.com/articles/18636/\u003c/li\u003e\n\u003cli\u003eScheen AJ (2011) Cytochrome P450-mediated cardiovascular drug interactions. Expert Opinion on Drug Metabolism and Toxicology 7(9):1065-1082.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1517/17425255.2011.586337\u003c/li\u003e\n\u003cli\u003eBIOVIA, Dassault Syst\u0026egrave;mes. (2022). \u003cem\u003eDiscovery Studio Visualizer\u003c/em\u003e\u003cem\u003e \u003c/em\u003e(Version 2022). San Diego: Dassault Syst\u0026egrave;mes. Available at: https://www.3ds.com/products-services/biovia/products/molecular-modeling-simulation/biovia-discovery-studio/\u003c/li\u003e\n\u003cli\u003eMathew D, Hsu WL (2018) Antiviral potential of curcumin. Journal of Functional Foods 40:692-699.\u003cspan dir=\"RTL\"\u003e\u0026rlm; \u003c/span\u003ehttps://doi.org/10.1016/j.jff.2017.12.017\u003c/li\u003e\n\u003cli\u003eSharma A, Sharma T, Bhaskar R, et al (2024) Promising potential of curcumin and related compounds for antiviral drug discovery. Medicinal Chemistry 20(6):597-612.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttp://dx.doi.org/10.2174/0115734064277371240325105016\u003c/li\u003e\n\u003cli\u003eHussain Y, Alam W, Ullah H, et al (2022) Antimicrobial potential of curcumin: therapeutic potential and challenges to clinical applications. Antibiotics 11(3):322.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.3390/antibiotics11030322\u003c/li\u003e\n\u003cli\u003eGong G, Guan YY, Zhang ZL, et al (2020) Isorhamnetin: A review of pharmacological effects. Biomedicine and Pharmacotherapy 128:110301. https://doi.org/10.1016/j.biopha.2020.110301\u003c/li\u003e\n\u003cli\u003eLee WH, Loo CY, Bebawy M, et al (2013) Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21\u003csup\u003est\u003c/sup\u003e century. Current Neuropharmacology 11(4):338-378.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.2174/1570159X11311040002\u003c/li\u003e\n\u003cli\u003eZorofchian Moghadamtousi S, Abdul Kadir H, Hassandarvish P, et al (2014) A review on antibacterial, antiviral, and antifungal activity of Curcumin. BioMed Research International (1):186864.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1155/2014/186864\u003c/li\u003e\n\u003cli\u003eOglah MK, Mustafa YF, Bashir MK, et al (2020) Curcumin and its derivatives: A review of their biological activities. Systematic Reviews in Pharmacy 11(3):472-481.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.5530/srp.2020.3.60\u003c/li\u003e\n\u003cli\u003eBadshah SL, Faisal S, Muhammad A, et al (2021) Antiviral activities of flavonoids. Biomedicine and Pharmacotherapy 140:111596.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1016/j.biopha.2021.111596\u003c/li\u003e\n\u003cli\u003eShahrajabian MH, Sun W, Cheng Q (2022) The importance of flavonoids and phytochemicals of medicinal plants with antiviral activities. Mini-Reviews in Organic Chemistry 19(3):293-318.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttp://dx.doi.org/10.2174/1570178618666210707161025\u003c/li\u003e\n\u003cli\u003eNaithani R, Huma LC, Holland LE, et al (2008) Antiviral activity of phytochemicals: a comprehensive review. Mini Reviews in Medicinal Chemistry 8(11):1106-1133.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttp://dx.doi.org/10.2174/138955708785909943\u003c/li\u003e\n\u003cli\u003eKom\u0026iacute;nek P, Kom\u0026iacute;nkov\u0026aacute; M, Jandov\u0026aacute; B (2016) Effect of repeated Ribavirin treatment on grapevine viruses. Acta Virologica 60(4):400-403.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003edoi:10.4149/av_2016_04_400\u003c/li\u003e\n\u003cli\u003eEgerman RS (2019) New antiviral agents for treatment of hepatitis C. Clinical Obstetrics and Gynecology 62(4):823-834.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1097/grf.0000000000000457\u003c/li\u003e\n\u003cli\u003eNinfali P, Antonelli A, Magnani M, et al (2020) Antiviral properties of flavonoids and delivery strategies\u003cem\u003e. \u003c/em\u003eNutrients 12(9):2534.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.3390/nu12092534\u003c/li\u003e\n\u003cli\u003eMeng XY, Zhang HX, Mezei M, et al (2011). Molecular docking: a powerful approach for structure-based drug discovery. Current Computer-aided Drug Design 7(2):146-157. https://doi.org/10.2174/157340911795677602\u003c/li\u003e\n\u003cli\u003eWarren GL, Andrews CW, Capelli AM, et al (2006) A critical assessment of docking programs and scoring functions. Journal of medicinal chemistry, 49(20):5912-5931. https://doi.org/10.1021/jm050362n\u003c/li\u003e\n\u003cli\u003eKitchen DB, Decornez H, Furr JR, et al (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nature reviews Drug discovery\u003cem\u003e \u003c/em\u003e3(11):935-949. https://doi.org/10.1038/nrd1549\u003c/li\u003e\n\u003cli\u003eGopal SM, Klumpers F, Herrmann C, et al (2017) Solvent effects on ligand binding to a serine protease. Physical Chemistry Chemical Physics 19(17):10753-10766.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1039/C6CP07899K\u003c/li\u003e\n\u003cli\u003eSeow-Neng C, Abu Bakar N, Mahmood M, et al (2017) Alternative strategy in crop protection: protease inhibitors from turmeric. Crop Improvement: Sustainability Through Leading-Edge Technology 253-270.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1007/978-3-319-65079-1_11\u003c/li\u003e\n\u003cli\u003eRizk MN, Ketta HA, Shabana YM (2024) Discovery of novel Trichoderma-based bioactive compounds for controlling potato virus Y based on molecular docking and molecular dynamics simulation techniques. Chemical and Biological Technologies in Agriculture 11(1):110.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1186/s40538-024-00629-2\u003c/li\u003e\n\u003cli\u003eJiang S, Debnath AK (2000) A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. Biochemical and Biophysical Research Communications 270(1):153-157.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1006/bbrc.2000.2411\u003c/li\u003e\n\u003cli\u003eGhosh AK, Chapsal BD, Weber IT, et al (2008) Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Accounts of Chemical Research 41(1):78-86.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003e https://doi.org/10.1021/ar7001232\u003c/li\u003e\n\u003cli\u003eAgback P, Agback T (2018) Direct evidence of a low barrier hydrogen bond in the catalytic triad of a serine protease. Scientific Reports 8(1):10078. https://doi.org/10.1038/s41598-018-28441-7\u003c/li\u003e\n\u003cli\u003eMulu A, Gajaa M, Woldekidan HB (2021) The impact of Curcumin derived polyphenols on the structure and flexibility COVID-19 main protease binding pocket: A molecular dynamics simulation study. Peer Journal 9:e11590.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.7717/peerj.11590\u003c/li\u003e\n\u003cli\u003eWang DP, Rizzo RC, Tirado-Rives J, et al (2001) Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs. Bioorganic and medicinal chemistry letters 11(21):2799-2802.\u003cstrong\u003e\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003e\u003c/strong\u003ehttps://doi.org/10.1016/S0960-894X(01)00510-8\u003c/li\u003e\n\u003cli\u003ePoongavanam V, Namasivayam V, Vanangamudi M, et al (2018) Integrative approaches in HIV‐1 non‐nucleoside reverse transcriptase inhibitor design. Wiley Interdisciplinary Reviews: Computational Molecular Science 8(1):e1328.\u003cspan dir=\"RTL\"\u003e \u0026rlm;\u003c/span\u003e\u003cspan dir=\"RTL\"\u003e\u003cspan dir=\"LTR\"\u003ehttps://doi.org/10.1002/wcms.1328\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\n\u003cli\u003eBai L, Wei C, Zhang J, et al (2023) Design, synthesis, and anti-PVY biological activity of 1, 3, 5-triazine derivatives containing piperazine structure. International Journal of Molecular Sciences 24(9):8280.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.3390/ijms24098280\u003c/li\u003e\n\u003cli\u003eEkowati J, Widyowati R, Norhayati, et al (2023) Chemopreventive Practices in Traditional Medicine. In \u003cem\u003eHerbal Medicine Phytochemistry\u003c/em\u003e: Applications and Trends (pp. 1-54). Cham: Springer International Publishing.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1007/978-3-031-21973-3_28-1\u003c/li\u003e\n\u003cli\u003eLiu X, Wang XJ (2020) Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. Journal of Genetics and Genomics 47(2):119-121.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1016/j.jgg.2020.02.001\u003c/li\u003e\n\u003cli\u003eCaughey B, Raymond LD, Raymond GJ, et al (2003) Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. Journal of Virology 77(9):5499-5502.\u003cstrong\u003e\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003e\u003c/strong\u003ehttps://doi.org/10.1128/jvi.77.9.5499-5502.2003\u003c/li\u003e\n\u003cli\u003eDu YN, Jia J, Yan JN, et al (2024) Non-covalent interactions between large yellow croaker (\u003cem\u003ePseudosciaena crocea\u003c/em\u003e) roe protein isolates and curcumin: Implications for enhanced curcumin delivery. Food Bioscience 60:104270.\u003cstrong\u003e\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003e\u003c/strong\u003ehttps://doi.org/10.1016/j.fbio.2024.104270\u003c/li\u003e\n\u003cli\u003eRoss IA (2024) Brassicaceae and Viral Diseases. In Plant-Based Therapeutics, Volume 2:\u003cem\u003e \u003c/em\u003eThe Brassicaceae Family (pp. 673-733). Cham: Springer Nature Switzerland.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1007/978-3-031-63681-3_14\u003c/li\u003e\n\u003cli\u003eShahhamzehei N, Abdelfatah S, Efferth T (2022) In silico and \u003cem\u003ein vitro\u003c/em\u003e identification of pan-coronaviral main protease inhibitors from a large natural product library. Pharmaceuticals 15(3):308.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.3390/ph15030308\u003c/li\u003e\n\u003cli\u003eFakih TM, Zainul R, Muchtaridi M. (2024) Molecular docking-based virtual screening and computational investigations of biomolecules (\u003cem\u003eCurcumin analogs\u003c/em\u003e) as potential lead inhibitors for SARS-CoV-2 papain-like protease. Pharmacia 71:1-19.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.3897/pharmacia.71.e123948\u003c/li\u003e\n\u003cli\u003eHelmy N, Afifi S, Othman B, El-Dougdoug K, et al (2023) Enhance potato resistance to Potato virus Y\u003csup\u003eNTN\u003c/sup\u003e using Curcumin nanoparticles: Inhibitory effects of curcumin nanoparticles on potato plants infected by \u003cem\u003ePotato virus Y\u003c/em\u003e. Acta Fytotechnica et Zootechnica 26(3):1336-9245. https://orcid.org/0000-0003-2191-8446\u003c/li\u003e\n\u003cli\u003eMbese Z, Khwaza V, Aderibigbe BA (2019) Curcumin and its derivatives as potential therapeutic agents in prostate, colon and breast cancers. Molecules 24(23):4386.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.3390/molecules24234386\u003c/li\u003e\n\u003cli\u003eElgorban AM, Debnath S, Bahkali AH, et al (2023) Exploring the potency of curcumin and phyto-compounds as inhibitors of tomato yellow leaf curl virus-sardinia\u0026apos;s DNA-binding domain: a computational approach. Physiological and Molecular Plant Pathology 127:102098.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003e\u003ccite\u003e \u003c/cite\u003ehttps://doi.org/10.1016/j.pmpp.2023.102098\u003c/li\u003e\n\u003cli\u003eSindhuja A, Vimalavathini RR, Kavimani S (2021) In silico docking studies of antiglycation activity of isorhamnetin on molecular proteins of advanced glycation end product (AGE) Pathway. Biomedical and Pharmacology Journal 14(4):2299-2307.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://dx.doi.org/10.13005/bpj/2331\u003c/li\u003e\n\u003cli\u003eHidayati WN, Apriasti R, Addy HS, et al (2021) Distinguishing resistances of transgenic sugarcane generated from RNA interference and pathogen derived resistance approaches to combating \u003cem\u003eSugarcane mosaic virus\u003c/em\u003e. Indonesian Journal of Biotechnology 26(2):107114. https://pdfs.semanticscholar.org/1eef/dd0264d37a35ec7eaa0279dd026c40193003.pdf\u003c/li\u003e\n\u003cli\u003eLi Y, Jiao J, Qi Y, et al (2021) Curcumin: A review of experimental studies and mechanisms related to periodontitis treatment. Journal of Periodontal Research 56(5):837-847.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1111/jre.12914\u003c/li\u003e\n\u003cli\u003eSitohy M, Taha S, Abdel-Hamid M, et al (2021) Protecting potato plants against PVX and PVY viral infections by the application of native and chemically modified legume proteins. Journal of Plant Diseases and Protection 128:1101-1114.\u003cspan dir=\"RTL\"\u003e\u0026rlm;\u003c/span\u003ehttps://doi.org/10.1007/s41348-021-00448-9\u003c/li\u003e\n\u003cli\u003eElshaer NA, El-Masry SS, Rabiee MS, et al (2025) In Silico prediction of the potential of some bioactive compounds from Licorice to target \u003cem\u003eBanana bunchy top virus\u003c/em\u003e. Egyptian Journal of Phytopathology 53(1):194-224. https://doi.org/10.21608/ejp.2025.436169\u003cstrong\u003e\u003cbr\u003e\u003c/strong\u003e\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"beni-suef-university-journal-of-basic-and-applied-sciences","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"jbas","sideBox":"Learn more about [Beni-Suef University Journal of Basic and Applied Sciences](https://bjbas.springeropen.com)","snPcode":"43088","submissionUrl":"https://submission.springernature.com/new-submission/43088/3","title":"Beni-Suef University Journal of Basic and Applied Sciences","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"Antiviral activity, Curcumin, In silico, Molecular docking, Turmeric","lastPublishedDoi":"10.21203/rs.3.rs-7083267/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7083267/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eBackground: This study explores the antiviral potential of turmeric-derived compounds, particularly curcuminoids, against Potato Virus Y (PVY) strain PVY\u003csup\u003eN\u003c/sup\u003e-Egypt through in silico molecular docking simulations. The binding interactions of curcumin, bisdemethoxycurcumin, demethoxycurcumin, isorhamnetin, and ribavirin with three key viral proteins—P1 protease, helper component proteinase (HCPro), and coat protein (CP)—were evaluated to assess their therapeutic potential.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults \u003c/strong\u003eMolecular docking results showed that isorhamnetin had the strongest binding affinity for P1 protease, while curcumin and bisdemethoxycurcumin exhibited favorable binding to both HCPro and CP. The study further analyzed the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiles of the compounds, revealing that most ligands, except curcuminol and ribavirin, demonstrated good oral bioavailability and favorable gastrointestinal absorption. Toxicity concerns were noted for curcuminol and ribavirin. Curcumin and its derivatives, particularly isorhamnetin, emerged as promising antiviral candidates, with bisdemethoxycurcumin showing potential to inhibit viral replication. Ribavirin, while exhibiting moderate binding, presented fewer favorable interactions compared to curcumin derivatives.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion \u003c/strong\u003eThis work provides valuable insights into the design of antiviral agents targeting PVY and suggests that curcumin derivatives may offer an effective solution for PVY management, warranting further experimental validation and optimization for agricultural and pharmaceutical applications.\u003c/p\u003e","manuscriptTitle":"Antiviral Activity of Turmeric (Curcuma longa) Against Potato Virus Y: In Silico Molecular Docking Analysis ","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-08-12 21:06:37","doi":"10.21203/rs.3.rs-7083267/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-08-15T12:58:01+00:00","index":"","fulltext":""},{"type":"reviewerAgreed","content":"216266123998151066537300099380833663721","date":"2025-08-14T22:03:26+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-08-12T17:56:25+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"329314384695751169650458952726465926272","date":"2025-08-12T16:54:13+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-08-09T18:49:09+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"134888120406874152391038900056382991352","date":"2025-08-09T15:18:15+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"25548993514962977608158675387502612264","date":"2025-08-09T13:51:14+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-08-09T11:30:44+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-08-08T05:30:02+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"240918225620932713583004353827501551818","date":"2025-08-08T00:49:13+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"145908452172964371820215304631800334136","date":"2025-08-07T13:17:46+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"35818614949546817132215957766515657718","date":"2025-08-07T11:58:17+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"26796270385254202410975123490224690480","date":"2025-08-07T10:39:29+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"249176380713547346593057311154066119366","date":"2025-08-07T09:46:50+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"20176626851038580073391561132283844354","date":"2025-08-07T09:22:06+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-08-07T09:18:46+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-07-31T22:55:53+00:00","index":"","fulltext":""},{"type":"submitted","content":"Beni-Suef University Journal of Basic and Applied Sciences","date":"2025-07-29T23:43:55+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"beni-suef-university-journal-of-basic-and-applied-sciences","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"jbas","sideBox":"Learn more about [Beni-Suef University Journal of Basic and Applied Sciences](https://bjbas.springeropen.com)","snPcode":"43088","submissionUrl":"https://submission.springernature.com/new-submission/43088/3","title":"Beni-Suef University Journal of Basic and Applied Sciences","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"737ad280-c3a8-4efd-b365-a0f4b07045f5","owner":[],"postedDate":"August 12th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-09-08T16:00:03+00:00","versionOfRecord":{"articleIdentity":"rs-7083267","link":"https://doi.org/10.1186/s43088-025-00686-y","journal":{"identity":"beni-suef-university-journal-of-basic-and-applied-sciences","isVorOnly":false,"title":"Beni-Suef University Journal of Basic and Applied Sciences"},"publishedOn":"2025-09-03 15:57:27","publishedOnDateReadable":"September 3rd, 2025"},"versionCreatedAt":"2025-08-12 21:06:37","video":"","vorDoi":"10.1186/s43088-025-00686-y","vorDoiUrl":"https://doi.org/10.1186/s43088-025-00686-y","workflowStages":[]},"version":"v1","identity":"rs-7083267","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7083267","identity":"rs-7083267","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}